Introduction {#s1}
============

Histopathology is among the most important and widely used methods for diagnosing human disease and studying the development of multicellular organisms. As commonly performed, imaging of formalin-fixed, paraffin-embedded (FFPE) tissue has relatively low dimensionality, primarily comprising Hematoxylin and Eosin (H&E) staining supplemented by immunohistochemistry (IHC). The potential of IHC to aid in diagnosis and prioritization of therapy is well established ([@bib4]), but IHC is primarily a single-channel method: imaging multiple antigens usually involves the analysis of sequential tissue slices or harsh stripping protocols (although limited multiplexing is possible using IHC and bright-field imaging \[[@bib45]; [@bib48]\]). Antibody detection via formation of a brown diamino-benzidine (DAB) or similar precipitates are also less quantitative than fluorescence ([@bib41]). The limitations of IHC are particularly acute when it is necessary to quantify complex cellular states and multiple cell types, such as tumor infiltrating regulatory and cytotoxic T cells ([@bib39]) in parallel with tissue and pharmaco-dynamic markers.

Advances in DNA and RNA profiling have dramatically improved our understanding of oncogenesis and propelled the development of targeted anticancer drugs ([@bib13]). Sequence data are particularly useful when an oncogenic driver is both a drug target and a biomarker of drug response, such as *BRAF^V600E^* in melanoma ([@bib8]) or *BCR-ABL* in chronic myelogenous leukemia ([@bib11]). However, in the case of drugs that act through cell non-autonomous mechanisms, such as immune checkpoint inhibitors, tumor-drug interaction must be studied in the context of multicellular environments that include both cancer and non-malignant stromal and infiltrating immune cells. Multiple studies have established that these components of the tumor microenvironment strongly influence the initiation, progression and metastasis of cancer ([@bib19]) and the magnitude of responsiveness or resistance to immunotherapies ([@bib49]).

Single-cell transcriptome profiling provides a means to dissect tumor ecosystems at a molecular level and quantify cell types and states ([@bib47]). However, single-cell sequencing usually requires disaggregation of tissues, resulting in loss of spatial context ([@bib47]; [@bib36]). As a consequence, a variety of multiplexed approaches to analyzing tissues have recently been developed with the goal of simultaneously assaying cell identity, state, and morphology ([@bib16]; [@bib14]; [@bib32]; [@bib40]; [@bib15]). For example, FISSEQ ([@bib26]) enables genome-scale RNA profiling of tissues at single-cell resolution, and multiplexed ion beam imaging (MIBI) and imaging mass cytometry achieve a high degree of multiplexing using antibodies as reagents, metals as labels and mass spectrometry as a detection modality ([@bib16]; [@bib2]). Despite the potential of these new methods, they require specialized instrumentation and consumables, which is one reason that the great majority of basic and clinical studies still rely on H&E and single-channel IHC staining. Moreover, methods that involve laser ablation of samples such as MIBI inherently have a lower resolution than optical imaging.

Thus, there remains a need for highly multiplexed tissue analysis methods that (i) minimize the requirement for specialized instruments and costly, proprietary reagents, (ii) work with conventionally prepared FFPE tissue specimens collected in clinical practice and research settings, (iii) enable imaging of ca. 50 antigens at subcellular resolution across a wide range of cell and tumor types, (iv) collect data with sufficient throughput that large specimens (several square centimeters) can be imaged and analyzed, (v) generate high-resolution data typical of optical microscopy, and (vi) allow investigators to customize the antibody mix to specific questions or tissue types. Among these requirements the last is particularly critical: at the current early stage of development of high dimensional histology, it is essential that individual research groups be able to test the widest possible range of antibodies and antigens in search of those with the greatest scientific and diagnostic value.

This paper describes a method for highly multiplexed fluorescence imaging of tissues, tissue-based cyclic immunofluorescence (t-CyCIF), inspired by a cyclic method first described by [@bib14]). t-CyCIF also extends a method we previously described for imaging cells grown in culture ([@bib28]). In its current implementation, t-CyCIF assembles up to 60-plex images of FFPE tissue sections via successive rounds of four-channel imaging. t-CyCIF uses widely available reagents, conventional slide scanners and microscopes, manual or automated slide processing and simple protocols. It can, therefore, be implemented in most research or clinical laboratories on existing equipment. Our data suggest that high-dimensional imaging methods using cyclic immunofluorescence have the potential to become a robust and widely-used complement to single-cell genomics, enabling routine analysis of tissue and cancer morphology and phenotypes at single-cell resolution.

Results {#s2}
=======

t-CyCIF enables multiplexed imaging of FFPE tissue and tumor specimens at subcellular resolution {#s2-1}
------------------------------------------------------------------------------------------------

Cyclic immunofluorescence ([@bib14]) creates highly multiplexed images using an iterative process (a cycle) in which conventional low-plex fluorescence images are repeatedly collected from the same sample and then assembled into a high-dimensional representation. In the implementation described here, samples \~5 µm thick are cut from FFPE blocks, the standard in most histopathology services, followed be dewaxing and antigen retrieval either manually or on automated slide strainers in the usual manner ([@bib44]). To reduce auto-fluorescence and non-specific antibody binding, a cycle of 'pre-staining' is performed; this involves incubating the sample with secondary antibodies followed by fluorophore oxidation in a high pH hydrogen peroxide solution in the presence of light ('fluorophore bleaching'). Subsequent t-CyCIF cycles each involve four steps ([Figure 1A](#fig1){ref-type="fig"}): (i) immuno-staining with antibodies against protein antigens (three antigens per cycle in the implementation described here) (ii) staining with a DNA dye (commonly Hoechst 33342) to mark nuclei and facilitate image registration across cycles (iii) four-channel imaging at low- and high-magnification (iv) fluorophore bleaching followed by a wash step and then another round of immuno-staining. In t-CyCIF, the signal-to-noise ratio often increases with cycle number due to progressive reductions in background intensity over the course of multiple rounds of fluorophore bleaching. This effect is visible in [Figure 1B](#fig1){ref-type="fig"} as the gradual disappearance of an auto-fluorescent feature (denoted by a dotted white oval and quantified in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; see detailed analysis below). When no more t-CyCIF cycles are to be performed, the specimen is stained with H&E to enable conventional histopathology review. Individual image panels are stitched together and registered across cycles followed by image processing and segmentation to identify cells and other structures. t-CyCIF allows for one cycle of indirect immunofluorescence using secondary antibodies. In all other cycles antibodies are directly conjugated to fluorophores, typically Alexa 488, 555 or 647 (for a description of different modes of CyCIF see [@bib28]). As an alternative to chemical coupling we have tested the Zenon antibody labeling method ([@bib46]) from ThermoFisher in which isotype-specific Fab fragments pre-labeled with fluorophores are bound to primary antibodies to create immune complexes; the immune complexes are then incubated with tissue samples ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). This method is effective with 30--40% of the primary antibodies that we have tested and potentially represents a simple way to label a wide range of primary antibodies with different fluorophores.

![Steps in the t-CyCIF process.\
(**A**) Schematic of the cyclic process whereby t-CyCIF images are assembled via multiple rounds of four-color imaging. (**B**) Image of human tonsil prior to pre-staining and then over the course of three rounds of t-CyCIF. The dashed circle highlights a region with auto-fluorescence in both green and red channels (used for Alexa-488 and Alexa-647, respectively) and corresponds to a strong background signal. With subsequent inactivation and staining cycles (three cycles shown here), this background signal becomes progressively less intense; the phenomenon of decreasing background signal and increasing signal-to-noise ratio as cycle number increases was observed in several staining settings (see also [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).](elife-31657-fig1){#fig1}

Imaging of t-CyCIF samples can be performed on a variety of fluorescent microscopes each of which represent a different tradeoff between data acquisition time, image resolution and sensitivity ([Table 1](#table1){ref-type="table"}). Greater resolution (a higher numerical aperture objective lens) typically corresponds to a smaller field of view and thus, longer acquisition time for large specimens. Imaging of specimens several square centimeters in area at a resolution of \~1 µm is routinely performed on microscopes specialized for scanning slides (slide scanners); we use a CyteFinder system from RareCyte (Seattle WA) configured with 10 × 0.3 NA and 40 × 0.6 NA objectives but have tested scanners from Leica, Nikon and other manufacturers. [Figure 2A--B](#fig2){ref-type="fig"} show an H&E image of a \~10 × 11 mm metastatic melanoma specimen and a t-CyCIF image assembled from 165 individual image tiles. The assembly process involves stitching sequential image tiles from a single t-CyCIF cycle into one large image panel, flat-fielding to correct for uneven illumination and registration of images from successive t-CyCIF cycles to each other; these procedures were performed using ImageJ, ASHLAR, and BaSiC software as described in materials and methods ([@bib37]).

![Multi-scale imaging of t-CyCIF specimens.\
(**A**) Bright-field H&E image of a metastasectomy specimen that includes a large metastatic melanoma lesion and adjacent benign tissue. The H&E staining was performed after the same specimen had undergone t-CyCIF. (**B**) Representative t-CyCIF staining of the specimen shown in (**A**) stitched together using the *Ashlar* software from 165 successive CyteFinder fields using a 20X/0.8NA objective. (**C**) One field from (**B**) at the tumor-normal junction demonstrating staining for S100-postive malignant cells, α-SMA positive stroma, T lymphocytes (positive for CD3, CD4 and CD8), and the proliferation marker phospho-RB (pRB). (**D**) A melanoma tumor imaged on a GE INCell Analyzer 6000 confocal microscope to demonstrate sub-cellular and sub-organelle structures. This specimen was stained with phospho-Tyrosine (pTyr), Lamin A/C and p-Aurora A/B/C and imaged with a 60X/0.95NA objective. pTyr is localized in membrane in patches associated with receptor-tyrosine kinase, visible here as red punctate structures. Lamin A/C is a nuclear membrane protein that outlines the vicinity of the cell nucleus in this image. Aurora kinases A/B/C coordinate centromere and centrosome function and are visible in this image bound to chromosomes within a nucleus of a mitotic cell in prophase (yellow arrow). (**E**) Staining of a melanoma sample using the GE OMX Blaze structured illumination microscope with a 60X/1.42NA objective shows heterogeneity of structural proteins of the nucleus, including as Lamin B and Lamin A/C (indicated by yellow arrows) and part of the nuclear pore complex (NUP98) that measures \~120 nm in total size and indirectly allows the visualization of nuclear pores (indicated by non-continuous staining of NUP98). (**F**) Staining of a patient-derived mouse xenograft breast tumor using the OMX Blaze with a 60x/1.42NA objective shows a spindle in a mitotic cell (beta-tubulin in red) as well as vesicles staining positive for VEGFR2 (in cyan) and punctuate expression of the EGFR in the plasma membrane (in green).](elife-31657-fig2){#fig2}
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###### Microscopes used in this study and their properties.

  --------------------------------------------------------------------------------------------------
  Instrument                Type                      Objective      Field of view    Nominal\
                                                                                      Resolution\*
  ------------------------- ------------------------- -------------- ---------------- --------------
  RareCyte Cytefinder       Slide Scanner             10X/0.3 NA     1.6 × 1.4 mm     1.06 µm

  20X/0.8NA                 0.8 × 0.7 mm              0.40 µm                         

  40X/0.6 NA                0.42 × 0.35 mm            0.53 µm                         

  GE INCell Analyzer 6000   Confocal                  60X/0.95 NA    0.22 × 0.22 mm   0.21 µm

  GE OMX Blaze              Structured\               60 × 1.42 NA   0.08 × 0.08 mm   0.11 µm
                            Illumination Microscope                                   
  --------------------------------------------------------------------------------------------------

\*Except in the case of the OMX Blaze, nominal resolution was calculated using the formula (r) = 0.61λ/NA for widefield and (r) = 0.4λ/NA for confocal microscopy with λ = 520 nm. Actual resolution depends on optical properties and thickness of sample, alignment and quality of the optical components in the light path. For structured illumination microscopy, actual resolution depends on accurate matching of immersion oil refractive index with sample in the Cy3 channel and use of an optimal point spread function during reconstruction process. The resolution in other channels will be sub-nominal.

In the t-CyCIF image ([Figure 2B](#fig2){ref-type="fig"}) tumor cells staining positive for S100 (a melanoma marker in green \[[@bib20]\]) are surrounded by CD45-positive immune cells (CD45RO^+^ cells in white) and by stromal cells expressing the alpha isoform of smooth muscle actin (α-SMA in red). By zooming in on one tile, single cells can be identified and characterized ([Figure 2C](#fig2){ref-type="fig"}); in this image, CD4^+^ and CD8^+^ T-lymphocytes and proliferating pRB^+^ positive cells are visible. At 60X resolution on a confocal GE INCell Analyzer 6000, kinetochores stain positive for the phosphorylated form of the Aurora A/B/C kinase and can be counted in a mitotic cell (yellow arrowhead in [Figure 2D](#fig2){ref-type="fig"}). Nominally super-resolution imaging on a GE OMX Blaze Structured Illumination Microscope ([@bib7]) (using a 60 × 1.42 Plan Apo objective) reveals very fine structural details including differential expression of Lamin isotypes (in a melanoma, [Figure 2E](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) and mitotic spindle fibers (in cells of a xenograft tumor; [Figure 2F](#fig2){ref-type="fig"} and [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). These data show that t-CyCIF images have readily interpretable features at the scale of an entire tumor, individual tumor cells and subcellular structures. Little subcellular (or super-resolution) imaging of clinical FFPE specimens has been reported to date (but see [@bib9]), but fine subcellular morphology has the potential to provide dramatically greater information than simple integration of antibody intensities across whole cells.

To date, we have tested commercial antibodies against \~200 different proteins for their compatibility with t-CyCIF; these include lineage makers, cytoskeletal proteins, cell cycle regulators, the phosphorylated forms of signaling proteins and kinases, transcription factors, markers of cell state including quiescence, senescence, apoptosis, stress, etc. as well as a variety of non-antibody-based fluorescent stains ([Table 2](#table2){ref-type="table"}). Multiplexing antibodies and stains makes it possible to discriminate among proliferating, quiescent and dying cells, identify tumor and stroma, and collect immuno-phenotypes ([@bib2]; [@bib16]; [@bib17]). Use of phospho-specific antibodies and antibodies against proteins that re-localize upon activation (e.g. transcription factors) makes it possible to assay the states of signal transduction networks. For example, in a 10-cycle t-CyCIF analysis of human tonsil ([Figure 3A](#fig3){ref-type="fig"}) subcellular features such as membrane staining, Ki-67 puncta (Cycle 1), ring-like staining of the nuclear lamina (Cycle 6) and nuclear exclusion of NF-$ĸ$B (Cycle 6) can easily be demonstrated ([Figure 3B](#fig3){ref-type="fig"}). The five-cycle t-CyCIF data on normal skin in [Figure 3C](#fig3){ref-type="fig"} shows tight localization of auto-fluorescence (likely melanin) to the epidermis prior to pre-bleaching and images of three non-antibody stains used in the last t-CyCIF cycle: HCS CellMask Red Stain for cytoplasm and nuclei, Actin Red, a Phalloidin-based stain for actin and Mito-tracker Green for mitochondria.

![t-CyCIF imaging of normal tissues.\
(**A**) Selected images of a tonsil specimen subjected to 10-cycle t-CyCIF to demonstrate tissue, cellular, and subcellular localization of tissue and immune markers (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for a list of antibodies). (**B**) Selected cycles from (**A**) demonstrating sub-nuclear features (Ki67 staining, cycle 1), immune cell distribution (cycle 2), structural proteins (E-Cadherin and Vimentin, cycle 5) and nuclear vs. cytosolic localization of transcription factors (NF-kB, cycle 6). (**C**) Five-cycle t-CyCIF of human skin to show the tight localization of some auto-fluorescence signals (Cycle 0), the elimination of these signals after pre-staining (Cycle 1), and the dispersal of rare cell types within a complex layered tissue (see [Supplementary file 1](#supp1){ref-type="supplementary-material"} for a list of the antibodies).](elife-31657-fig3){#fig3}
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###### List of antibodies tested and validated for t-CyCIF.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibody name       Target protein        Performance   Vendor              Catalog no.        Clone                     Fluorophore       Research resource\
                                                                                                                                             Identifier
  ------------------- --------------------- ------------- ------------------- ------------------ ------------------------- ----------------- --------------------
  Bax-488             Bax                   \*            BioLegend           633603             2D2                       Alexa Fluor 488   AB_2562171

  CD11b-488           CD11b                 \*            Abcam               AB204271           EPR1344                   Alexa Fluor 488   

  CD4-488             CD4                   \*            R and D Systems     FAB8165G           Polyclonal                Alexa Fluor 488   

  CD8a-488            CD8                   \*            eBioscience         53-0008-80         AMC908                    Alexa Fluor 488   AB_2574412

  cJUN-488            cJUN                  \*            Abcam               AB193780           E254                      Alexa Fluor 488   

  CK18-488            Cytokeratin 18        \*            eBioscience         53-9815-80         LDK18                     Alexa Fluor 488   AB_2574480

  CK8-FITC            Cytokeratin 8         \*            eBioscience         11-9938-80         LP3K                      FITC              AB_10548518

  CycD1-488           CycD1                 \*            Abcam               AB190194           EPR2241                   Alexa Fluor 488   

  Ecad-488            E-Cadherin            \*            CST                 3199               24E10                     Alexa Fluor 488   AB_10691457

  EGFR-488            EGFR                  \*            CST                 5616               D38B1                     Alexa Fluor 488   AB_10691853

  EpCAM-488           EpCAM                 \*            CST                 5198               VU1D9                     Alexa Fluor 488   AB_10692105

  HES1-488            HES1                  \*            Abcam               AB196328           EPR4226                   Alexa Fluor 488   

  Ki67-488            Ki67                  \*            CST                 11882              D3B5                      Alexa Fluor 488   AB_2687824

  LaminA/C-488        Lamin A/C             \*            CST                 8617               4C11                      Alexa Fluor 488   AB_10997529

  LaminB1-488         Lamin B1              \*            Abcam               AB194106           EPR8985(B)                Alexa Fluor 488   

  mCD3E-FITC          ms_CD3E               \*            BioLegend           100306             145--2 C11                FITC              AB_312671

  mCD4-488            ms_CD4                \*            BioLegend           100532             RM4-5                     Alexa Fluor 488   AB_493373

  MET-488             c-MET                 \*            CST                 8494               D1C2                      Alexa Fluor 488   AB_10999405

  mF4/80-488          ms_F4/80              \*            BioLegend           123120             BM8                       Alexa Fluor 488   AB_893479

  MITF-488            MITF                  \*            Abcam               AB201675           D5                        Alexa Fluor 488   

  Ncad-488            N-Cadherin            \*            BioLegend           350809             8C11                      Alexa Fluor 488   AB_11218797

  p53-488             p53                   \*            CST                 5429               7F5                       Alexa Fluor 488   AB_10695458

  PCNA-488            PCNA                  \*            CST                 8580               PC10                      Alexa Fluor 488   AB_11178664

  PD1-488             PD1                   \*            CST                 15131              D3W4U                     Alexa Fluor 488   

  PDI-488             PDI                   \*            CST                 5051               C81H6                     Alexa Fluor 488   AB_10950503

  pERK-488            pERK(T202/Y204)       \*            CST                 4344               D13.14.4E                 Alexa Fluor 488   AB_10695876

  pNDG1-488           pNDG1(T346)           \*            CST                 6992               D98G11                    Alexa Fluor 488   AB_10827648

  POL2A-488           POL2A                 \*            Novus Biologicals   NB200-598AF488     4H8                       Alexa Fluor 488   AB_2167465

  pS6(S240/244)−488   pS6(240/244)          \*            CST                 5018               D68F8                     Alexa Fluor 488   AB_10695861

  S100a-488           S100alpha             \*            Abcam               AB207367           EPR5251                   Alexa Fluor 488   

  SQSTM1-488          SQSTM1/p62            \*            CST                 8833               D1D9E3                    Alexa Fluor 488   

  STAT3-488           STAT3                 \*            CST                 14047              B3Z2G                     Alexa Fluor 488   

  Survivin-488        Survivin              \*            CST                 2810               71G4B7                    Alexa Fluor 488   AB_10691462

  Catenin-488         β-Catenin             \*            CST                 2849               L54E2                     Alexa Fluor 488   AB_10693296

  Actin-555           Actin                 \*            CST                 8046               13E5                      Alexa Fluor 555   AB_11179208

  CD11c-570           CD11c                 \*            eBioscience         41-9761-80         118/A5                    eFluor 570        AB_2573632

  CD3D-555            CD3D                  \*            Abcam               AB208514           EP4426                    Alexa Fluor 555   

  CD4-570             CD4                   \*            eBioscience         41-2444-80         N1UG0                     eFluor 570        AB_2573601

  CD45-PE             CD45                  \*            R and D Systems     FAB1430P-100       2D1                       PE                AB_2237898

  CK7-555             Cytokeratin 7         \*            Abcam               AB209601           EPR17078                  Alexa Fluor 555   

  cMYC-555            cMYC                  \*            Abcam               AB201780           Y69                       Alexa Fluor 555   

  E2F1-555            E2F1                  \*            Abcam               AB208078           EPR3818(3)                Alexa Fluor 555   

  Ecad-555            E-Cadherin            \*            CST                 4295               24E10                     Alexa Fluor 555   

  EpCAM-PE            EpCAM                 \*            BioLegend           324205             9C4                       PE                AB_756079

  FOXO1a-555          FOXO1a                \*            Abcam               AB207244           EP927Y                    Alexa Fluor 555   

  FOXP3-570           FOXP3                 \*            eBioscience         41-4777-80         236A/E7                   eFluor 570        AB_2573608

  GFAP-570            GFAP                  \*            eBioscience         41-9892-80         GA5                       eFluor 570        AB_2573655

  HSP90-PE            HSP90b                \*            Abcam               AB115641           Polyclonal                PE                AB_10936222

  KAP1-594            KAP1                  \*            BioLegend           619304             20A1                      Alexa Fluor 594   AB_2563298

  Keratin-555         pan-Keratin           \*            CST                 3478               C11                       Alexa Fluor 555   AB_10829040

  Keratin-570         pan-Keratin           \*            eBioscience         41-9003-80         AE1/AE3                   eFluor 570        AB_11217482

  Ki67-570            Ki67                  \*            eBioscience         41-5699-80         20Raj1                    eFluor 570        AB_11220088

  LC3-555             LC3                   \*            CST                 13173              D3U4C                     Alexa Fluor 555   

  MAP2-570            MAP2                  \*            eBioscience         41-9763-80         AP20                      eFluor 570        AB_2573634

  pAUR-555            pAUR1/2/3(T288/T2     \*            CST                 13464              D13A11                    Alexa Fluor 555   

  pCHK2-PE            pChk2(T68)            \*            CST                 12812              C13C1                     PE                

  PDL1-555            PD-L1/CD274           \*            Abcam               AB213358           28--8                     Alexa Fluor 555   

  pH3-555             pH3(S10)              \*            CST                 3475               D2C8                      Alexa Fluor 555   AB_10694639

  pRB-555             pRB(S807/811)         \*            CST                 8957               D20B12                    Alexa Fluor 555   

  pS6(235/236)--555   pS6(235/236)          \*            CST                 3985               D57.2.2E                  Alexa Fluor 555   AB_10693792

  pSRC-PE             pSRC(Y418)            \*            eBioscience         12-9034-41         SC1T2M3                   PE                AB_2572680

  S6-555              S6                    \*            CST                 6989               54D2                      Alexa Fluor 555   AB_10828226

  SQSTM1-555          SQSTM1/p62            \*            Abcam               AB203430           EPR4844                   Alexa Fluor 555   

  VEGFR2-555          VEGFR2                \*            CST                 12872              D5B1                      Alexa Fluor 555   

  VEGFR2-PE           VEGFR2                \*            CST                 12634              D5B1                      PE                

  Vimentin-555        Vimentin              \*            CST                 9855               D21H3                     Alexa Fluor 555   AB_10859896

  Vinculin-570        Vinculin              \*            eBioscience         41-9777-80         7F9                       eFluor 570        AB_2573646

  gH2ax-PE            gH2ax                 \*            BioLegend           613412             2F3                       PE                AB_2616871

  AKT-647             AKT                   \*            CST                 5186               C67E7                     Alexa Fluor 647   AB_10695877

  aSMA-660            aSMA                  \*            eBioscience         50-9760-80         1A4                       eFluor 660        AB_2574361

  B220-647            CD45R/B220            \*            BioLegend           103226             RA3-6B2                   Alexa Fluor 647   AB_389330

  Bcl2-647            Bcl2                  \*            BioLegend           658705             100                       Alexa Fluor 647   AB_2563279

  Catenin-647         Beta-Catenin          \*            CST                 4627               L54E2                     Alexa Fluor 647   AB_10691326

  CD20-660            CD20                  \*            eBioscience         50-0202-80         L26                       eFluor 660        AB_11151691

  CD45-647            CD45                  \*            BioLegend           304020             HI30                      Alexa Fluor 647   AB_493034

  CD8a-660            CD8                   \*            eBioscience         50-0008-80         AMC908                    eFluor 660        AB_2574148

  CK5-647             Cytokeratin 5         \*            Abcam               AB193895           EP1601Y                   Alexa Fluor 647   

  CoIIV-647           Collagen IV           \*            eBioscience         51-9871-80         1042                      Alexa Fluor 647   AB_10854267

  COXIV-647           COXIV                 \*            CST                 7561               3E11                      Alexa Fluor 647   AB_10994876

  cPARP-647           cPARP                 \*            CST                 6987               D64E10                    Alexa Fluor 647   AB_10858215

  FOXA2-660           FOXA2                 \*            eBioscience         50-4778-82         3C10                      eFluor 660        AB_2574221

  FOXP3-647           FOXP3                 \*            BioLegend           320113             206D                      Alexa Fluor 647   AB_439753

  gH2ax-647           H2ax(S139)            \*            CST                 9720               20E3                      Alexa Fluor 647   AB_10692910

  gH2ax-647           H2ax(S139)            \*            BioLegend           613407             2F3                       Alexa Fluor 647   AB_2114994

  HES1-647            HES1                  \*            Abcam               AB196577           EPR4226                   Alexa Fluor 647   

  Ki67-647            Ki67                  \*            CST                 12075              D3B5                      Alexa Fluor 647   

  Ki67-647            Ki67                  \*            BioLegend           350509             Ki-67                     Alexa Fluor 647   AB_10900810

  mCD45-647           ms_CD45               \*            BioLegend           103124             30-F11                    Alexa Fluor 647   AB_493533

  mCD4-647            ms_CD4                \*            BioLegend           100426             GK1.5                     Alexa Fluor 647   AB_493519

  mEPCAM-647          ms_EPCAM              \*            BioLegend           118211             G8.8                      Alexa Fluor 647   AB_1134104

  MHCI-647            MHCI/HLAA             \*            Abcam               AB199837           EP1395Y                   Alexa Fluor 647   

  MHCII-647           MHCII                 \*            Abcam               AB201347           EPR11226                  Alexa Fluor 647   

  mLy6C-647           ms_Ly6C               \*            BioLegend           128009             HK1.4                     Alexa Fluor 647   AB_1236551

  mTOR-647            mTOR                  \*            CST                 5048               7C10                      Alexa Fluor 647   AB_10828101

  NFkB-647            NFkB (p65)            \*            Abcam               AB190589           E379                      Alexa Fluor 647   

  NGFR-647            NGFR/CD271            \*            Abcam               AB195180           EP1039Y                   Alexa Fluor 647   

  NUP98-647           NUP98                 \*            CST                 13393              C39A3                     Alexa Fluor 647   

  p21-647             p21                   \*            CST                 8587               12D1                      Alexa Fluor 647   AB_10892861

  p27-647             p27                   \*            Abcam               AB194234           Y236                      Alexa Fluor 647   

  pATM-660            pATM(S1981)           \*            eBioscience         50-9046-41         10H11.E12                 eFluor 660        AB_2574312

  PAX8-647            PAX8                  \*            Abcam               AB215953           EPR18715                  Alexa Fluor 647   

  PDL1-647            PD-L1/CD274           \*            CST                 15005              E1L3N                     Alexa Fluor 647   

  pMK2-647            pMK2(T334)            \*            CST                 4320               27B7                      Alexa Fluor 647   AB_10695401

  pmTOR-660           pmTOR(S2448)          \*            eBioscience         50-9718-41         MRRBY                     eFluor 660        AB_2574351

  pS6_235--647        pS6(S235/S236)        \*            CST                 4851               D57.2.2E                  Alexa Fluor 647   AB_10695457

  pSTAT3-647          pSTAT3(Y705)          \*            CST                 4324               D3A7                      Alexa Fluor 647   AB_10694637

  pTyr-647            p-Tyrosine            \*            CST                 9415               p-Tyr-100                 Alexa Fluor 647   AB_10693160

  S100A4-647          S100A4                \*            Abcam               AB196168           EPR2761(2)                Alexa Fluor 647   

  Survivin-647        Survivin              \*            CST                 2866               71G4B7                    Alexa Fluor 647   AB_10698609

  TUBB3-647           TUBB3                 \*            BioLegend           657405             AA10                      Alexa Fluor 647   AB_2563609

  Tubulin-647         beta-Tubulin          \*            CST                 3624               9F3                       Alexa Fluor 647   AB_10694204

  Vimentin-647        Vimentin              \*            BioLegend           677807             O91D3                     Alexa Fluor 647   AB_2616801

  anti-14-3-3         14-3-3                \*            Santa Cruz          SC-629-G           Polyclonal                N/D               AB_630820

  anti-53BP1          53BP1                 \*            Bethyl              A303-906A          Polyclonal                N/D               AB_2620256

  anti-5HMC           5HMC                  \*            Active Motif        39769              Polyclonal                N/D               AB_10013602

  anti-CD11b          CD11b                 \*            Abcam               AB133357           EPR1344                   N/D               AB_2650514

  anti-CD2            CD2                   \*            Abcam               AB37212            Polyclonal                N/D               AB_726228

  anti-CD20           CD20                  \*            Dako                M0755              L26                       N/D               AB_2282030

  anti-CD3            CD3                   \*            Dako                A0452              Polyclonal                N/D               AB_2335677

  anti-CD4            CD4                   \*            Dako                M7310              4B12                      N/D               

  anti-CD45RO         CD45RO                \*            Dako                M0742              UCHL1                     N/D               AB_2237910

  anti-CD8            CD8                   \*            Dako                M7103              C8/144B                   N/D               AB_2075537

  anti-CycA2          CycA2                 \*            Abcam               AB38               E23.1                     N/D               AB_304084

  anti-ET1            ET-1                  \*            Abcam               AB2786             TR.ET.48.5                N/D               AB_303299

  anti-FAP            FAP                   \*            eBioscience         BMS168             F11-24                    N/D               AB_10597443

  anti-FOXP3          FOXP3                 \*            BioLegend           320102             206D                      N/D               AB_430881

  anti-LAMP2          LAMP2                 \*            Abcam               AB25631            H4B4                      N/D               AB_470709

  anti-MCM6           MCM6                  \*            Santa Cruz          SC-9843            Polyclonal                N/D               AB_2142543

  anti-PAX8           PAX8                  \*            Abcam               AB191870           EPR18715                  N/D               

  anti-PD1            PD1                   \*            CST                 86163              D4W2J                     N/D               

  anti-pEGFR          pEGFR(Y1068)          \*            CST                 3777               D7A5                      N/D               AB_2096270

  anti-pERK           pERK(T202/Y204)       \*            CST                 4370               D13.14.4E                 N/D               AB_2315112

  anti-pRB            pRB(S807/811)         \*            Santa Cruz          SC-16670           Polyclonal                N/D               AB_655250

  anti-pRPA32         pRPA32 (S4/S8)        \*            Bethyl              IHC-00422          Polyclonal                N/D               AB_1659840

  anti-pSTAT3         pSTAT3                \*\*          CST                 9145               D3A7                      N/D               AB_2491009

  anti-pTyr           pTyr                  \*            CST                 9411               p-Tyr-100                 N/D               AB_331228

  anti-RPA32          RPA32                 \*            Bethyl              IHC-00417          Polyclonal                N/D               AB_1659838

  anti-TPCN2          TPCN2                 \*            NOVUSBIO            NBP1-86923         Polyclonal                N/D               AB_11021735

  anti-VEGFR1         VEGFR1/FLT1           \*            Santa Cruz          SC-31173           Polyclonal                N/D               AB_2106885

  Abeta-488           Beta-Amyloid (1-16)   †             BioLegend           803013             6E10                      Alexa Fluor 488   AB_2564765

  BRAF-FITC           B-RAF                 †             Abcam               ab175637           K21-F                     FITC              

  BrdU-488            BrdU                  †             BioLegend           364105             3D4                       Alexa Fluor 488   AB_2564499

  cCasp3-488          cCasp3                †             R and D Systems     IC835G-025         269518                    Alexa Fluor 488   

  CD11b-488           CD11b                 †             BioLegend           101219             M1/70                     Alexa Fluor 488   AB_493545

  CD123-488           CD123                 †             BioLegend           306035             6H6                       Alexa Fluor 488   AB_2629569

  CD49b-FITC          CD49b                 †             BioLegend           359305             P1E6-C5                   FITC              AB_2562530

  CD69-FITC           CD69                  †             BioLegend           310904             FN50                      FITC              AB_314839

  CD71-FITC           CD71                  †             BioLegend           334103             CY1G4                     FITC              AB_1236432

  CD80-FITC           CD80                  †             R and D Systems     FAB140F            37711                     FITC              AB_357027

  CD8a-488            CD8a                  †             eBioscience         53-0086-41         OKT8                      Alexa Fluor 488   AB_10547060

  CDC2-FITC           CDC2/p34              †             Santa Cruz          SC-54 FITC         17                        FITC              AB_627224

  CycB1-FITC          CycB1                 †             Santa Cruz          SC-752 FITC        Polyclonal                FITC              AB_2072134

  FN-488              Fibronection          †             Abcam               AB198933           F1                        Alexa Fluor 488   

  IFNG-488            Interferron-Gamma     †             BioLegend           502517             4S.B3                     Alexa Fluor 488   AB_493030

  IL1-FITC            IL1                   †             BioLegend           511705             H1b-98                    FITC              AB_1236434

  IL6-FITC            IL6                   †             BioLegend           501103             MQ2-13A5                  FITC              AB_315151

  mCD31-FITC          ms_CD31               †             eBioscience         11-0311-82         390                       FITC              AB_465012

  mCD8a-488           ms_CD8a               †             BioLegend           100726             53--6.7                   Alexa Fluor 488   AB_493423

  Nestin-488          Nestin                †             eBioscience         53-9843-80         10C2                      Alexa Fluor 488   AB_1834347

  NeuN-488            NeuN                  †             Millipore           MAB377X            A60                       Alexa Fluor 488   AB_2149209

  PR-488              PR/PGR                †             Abcam               AB199224           YR85                      Alexa Fluor 488   

  Snail1-488          Snail1                †             eBioscience         53-9859-80         20C8                      Alexa Fluor 488   AB_2574482

  TGFB-FITC           TGFB1                 †             BioLegend           349605             TW4-2F8                   FITC              AB_10679043

  TNFa-488            TNFa                  †             BioLegend           502917             MAb11                     Alexa Fluor 488   AB_493122

  AR-555              AR                    †             CST                 8956               D6F11                     Alexa Fluor 555   AB_11129223

  CD11a-PE            CD11a                 †             BioLegend           301207             HI111                     PE                AB_314145

  CD11b-555           CD11b                 †             Abcam               AB206616           EPR1344                   Alexa Fluor 555   

  CD131-PE            CD131                 †             BD                  559920             JORO50                    PE                AB_397374

  CD14-PE             CD14                  †             eBioscience         12--0149           61D3                      PE                AB_10597598

  CD1a-PE             CD1a                  †             BioLegend           300105             HI149                     PE                AB_314019

  CD1c-PE             CD1c                  †             BioLegend           331505             L161                      PE                AB_1089000

  CD20-PE             CD20                  †             BioLegend           302305             2H7                       PE                AB_314253

  CD23-PE             CD23                  †             eBioscience         12-0232-81         B3B4                      PE                AB_465592

  CD31-PE             CD31                  †             eBioscience         12-0319-41         WM-59                     PE                AB_10670623

  CD31-PE             CD31                  †             R and D Systems     FAB3567P-025       9G11                      PE                AB_2279388

  CD34-PE             CD34                  †             Abcam               AB30377            QBEND/10                  PE                AB_726407

  CD45R-e570          CD45R/B220            †             eBioscience         41-0452-80         RA3-6B2                   eFluor 570        AB_2573598

  CD71-PE             CD71                  †             eBioscience         12-0711-81         R17217                    PE                AB_465739

  CD86-PE             CD86                  †             BioLegend           305405             IT2.2                     PE                AB_314525

  CK19-570            Cytokeratin 19        †             eBioscience         41-9898-80         BA17                      eFluor 570        AB_11218678

  HER2-570            HER2                  †             eBioscience         41-9757-80         MJD2                      eFluor 570        AB_2573628

  IL3-PE              IL3                   †             BD                  554383             MP2-8F8                   PE                AB_395358

  NFATc1-PE           NFATc1                †             BioLegend           649605             7A6                       PE                AB_2562546

  PDL1-PE             PD-L1/CD274           †             BioLegend           329705             29E.2A3                   PE                AB_940366

  pMAPK (T202/Y204)   pERK1/2(T202/Y20      †             CST                 14095              197G2                     PE                

  pMAPK (Y204/Y187)   pERK1/2(Y204/Y18      †             CST                 75165              D1H6G                     PE                

  pSTAT1-PE           pSTAT1(Y705)          †             BioLegend           686403             A15158B                   PE                AB_2616938

  ABCC1-647           ABCC1                 †             BioLegend           370203             QCRL-2                    Alexa Fluor 647   AB_2566664

  AnnexinV-674        N/D                   †             BioLegend           640911             NA                        Alexa Fluor 647   AB_2561293

  CD103-647           CD103                 †             BioLegend           350209             Ber-ACT8                  Alexa Fluor 647   AB_10640870

  CD25-647            CD25                  †             BioLegend           302617             BC96                      Alexa Fluor 647   AB_493046

  CD31-APC            CD31                  †             eBioscience         17-0319-41         WM-59                     APC               AB_10853188

  CD68-APC            CD68                  †             BioLegend           333809             Y1/82A                    APC               AB_10567107

  CD8a-647            CD8a                  †             BioLegend           344725             SK1                       Alexa Fluor 647   AB_2563451

  CD8a-647            CD8a                  †             R and D Systems     FAB1509R-025       37006                     Alexa Fluor 647   

  CycE-660            CycE                  †             eBioscience         50-9714-80         HE12                      eFluor 660        AB_2574350

  HIF1-647            HIF1                  †             BioLegend           359705             546--16                   Alexa Fluor 647   AB_2563331

  HP1-647             HP1                   †             Abcam               AB198391           EPR5777                   Alexa Fluor 647   

  mCD123-APC          ms_CD123              †             eBioscience         17-1231-81         5B11                      APC               AB_891363

  NGFR-647            NGFR/CD271            †             BD                  560326             C40-1457                  Alexa Fluor 647   AB_1645403

  pBTK-660            pBTK(Y551/Y511)       †             eBioscience         50-9015-80         M4G3LN                    eFluor 660        AB_2574306

  PD1-647             PD1                   †             Abcam               AB201825           EPR4877 (2)               Alexa Fluor 647   

  PR-660              PR/PGR                †             eBioscience         50-9764-80         KMC912                    eFluor 660        AB_2574363

  RUNX3-660           RUNX3                 †             eBioscience         50-9817-80         R3-5G4                    eFluor 660        AB_2574383

  SOX2-647            SOX2                  †             Abcam               AB192075           Polyclonal                Alexa Fluor 647   

  anti-53BP1          53BP1                 †             Millipore           MAB3802            BP13                      N/D               AB_2206767

  anti-Axl            Axl                   †             R and D             AF154              Polyclonal                N/D               AB_354852

  anti-CD11b          CD11b                 †             Abcam               AB52478            EP1345Y                   N/D               AB_868788

  anti-CD8a           CD8                   †             eBioscience         14-0085-80         C8/144B                   N/D               AB_11151339

  anti-CEP170         CEP170                †             Abcam               AB72505            Polyclonal                N/D               AB_1268101

  anti-cMYC           cMYC                  †             BioLegend           626801             9E10                      N/D               AB_2235686

  anti-CPS1           CPS1                  †             Abcam               AB129076           EPR7493-3                 N/D               AB_11156290

  anti-E2F1           E2F1                  †             ThermoFisher        MS-879-P1          KH95                      N/D               AB_143934

  anti-eEF2K          eEF2K                 †             Santa Cruz          SC-21642           K-19                      N/D               AB_640043

  anti-Emil1          Emil1                 †             Abcam               AB212397           EMIL/1176                 N/D               

  anti-FKHRL1         FKHRL1                †             Santa Cruz          SC-9812            Polyclonal                N/D               AB_640608

  anti-FLAG           FLAG                  †             Sigma               F1804              M2                        N/D               AB_262044

  anti-GranB          Granzyme_B            †             Dako                M7235              M7235                     N/D               AB_2114697

  anti-HMB45          HMB45                 †             Abcam               AB732              HMB45 + M2- 7C10 + M2-\   N/D               AB_305844
                                                                                                 9E3                                         

  anti-HSP90b         HSP90b                †             Santa Cruz          SC-1057            D-19                      N/D               AB_2121392

  anti-IL2Ra          IL2Ra                 †             Abcam               AB128955           EPR6452                   N/D               AB_11141054

  anti-LAMP2          LAMP2                 †             R and D             AF6228             Polyclonal                N/D               AB_10971818

  anti-MITF           MITF                  †             Abcam               AB12039            C5                        N/D               AB_298801

  anti-Ncad           N-Cadherin            †             Abcam               AB18203            Polyclonal                N/D               AB_444317

  anti-NCAM           NCAM                  †             Abcam               AB6123             ERIC-1                    N/D               AB_2149537

  anti-NF1            NF1                   †             Abcam               AB178323           McNFn27b                  N/D               

  anti-pCTD           Pol II CTD(S2)        †             Active Motif        61083              3E10                      N/D               AB_2687450

  anti-PD1            PD1                   †             CST                 43248              EH33                      N/D               

  anti-pTuberin       pTuberin(S664)        †             Abcam               AB133465           EPR8202                   N/D               AB_11157389

  anti-S100           S100                  †             Dako                Z0311              Polyclonal                N/D               AB_10013383

  anti-SIRT3          SIRT3                 †             CST                 2627               C73E3                     N/D               AB_2188622

  anti-TIA1           TIA1                  †             Santa Cruz          SC-1751            Polyclonal                N/D               AB_2201433

  anti-TLR3           TLR3                  †             Santa Cruz          SC-8691            Polyclonal                N/D               AB_2240700

  anti-TNFa           TNFa                  †             Abcam               AB11564            MP6-XT3                   N/D               AB_298170

  anti-TPCN2          TPCN2                 †             Abcam               AB119915           Polyclonal                N/D               AB_10903692

  CD11a-FITC          CD11a                 ‡             eBioscience         11-0119-41         HI111                     FITC              AB_10597888

  CD20-FITC           CD20                  ‡             BioLegend           302303             2H7                       FITC              AB_314251

  CD2-FITC            CD2                   ‡             BioLegend           300206             RPA-2.10                  FITC              AB_314030

  CD45RO-488          CD45RO                ‡             BioLegend           304212             UCHL1                     Alexa Fluor 488   AB_528823

  CD8a-488            CD8                   ‡             BioLegend           301024             RPA-T8                    Alexa Fluor 488   AB_2561282

  cJUN-FITC           cJUN                  ‡             Santa Cruz          SC-1694 FITC       Polyclonal                FITC              AB_631263

  CXCR5-FITC          CXCR5                 ‡             BioLegend           356913             J252D4                    FITC              AB_2561895

  Ecad-FITC           Ecad                  ‡             BioLegend           324103             67A4                      FITC              AB_756065

  FOXP3-488           FOXP3                 ‡             BioLegend           320011             150D                      Alexa Fluor 488   AB_439747

  MITF-488            MITF                  ‡             Novus Biologicals   NB100-56561AF488   21D1418                   Alexa Fluor 488   AB_838580

  NCAM-488            NCAM/CD56             ‡             Abcam               AB200333           EPR2566                   Alexa Fluor 488   

  NCAM-FITC           NCAM/CD56             ‡             ThermoFisher        11-0566-41         TULY56                    FITC              AB_2572458

  NGFR-FITC           NGFR/CD271            ‡             BioLegend           345103             ME20.4                    FITC              AB_1937226

  PD1-488             PD-1                  ‡             BioLegend           367407             NAT105                    Alexa Fluor 488   AB_2566677

  PD1-488             PD-1                  ‡             BioLegend           329935             EH12.2H7                  Alexa Fluor 488   AB_2563593

  pERK-488            pERK(T202/Y204)       ‡             CST                 4374               E10                       Alexa Fluor 488   AB_10705598

  pERK-488            pERK(T202/Y204)       ‡             CST                 4780               137F5                     Alexa Fluor 488   AB_10705598

  S100A4-FITC         S100A4                ‡             BioLegend           370007             NJ-4F3-D1                 FITC              AB_2572073

  SOX2-488            SOX2                  ‡             BioLegend           656109             14A6A34                   Alexa Fluor 488   AB_2563956

  CD133-PE            CD133                 ‡             eBioscience         12-1338-41         TMP4                      PE                AB_1582258

  cMyc-TRITC          cMYC                  ‡             Santa Cruz          SC-40 TRITC        9E10                      TRITC             AB_627268

  cPARP-555           cPARP                 ‡             CST                 6894               D64E10                    Alexa Fluor 555   AB_10830735

  CTLA4-PE            CTLA4                 ‡             BioLegend           369603             BNI3                      PE                AB_2566796

  GATA3-594           GATA3                 ‡             BioLegend           653816             16E10A23                  Alexa Fluor 594   AB_2563353

  GFAP-Cy3            GFAP                  ‡             Millipore           MAB3402C3          NA                        Cy3               AB_11213580

  Oct4-555            OCT_4                 ‡             CST                 4439               C30A3                     Alexa Fluor 555   AB_10922586

  p21-555             p21                   ‡             CST                 8493               12D1                      Alexa Fluor 555   AB_10860074

  PD1-PE              PD1                   ‡             BioLegend           329905             EH12.2H7                  PE                AB_940481

  PDGFRb-555          PDGFRb                ‡             Abcam               AB206874           Y92                       Alexa Fluor 555   

  pSTAT1-555          pSTAT1                ‡             CST                 8183               58D6                      Alexa Fluor 555   AB_10860600

  TIM1-PE             TIM1                  ‡             BioLegend           353903             1D12                      PE                AB_11125165

  cCasp3-647          cCasp3                ‡             CST                 9602               D3E9                      Alexa Fluor 647   AB_2687881

  CD103-APC           CD103                 ‡             eBioscience         17-1038-41         B-Ly7                     APC               AB_10669816

  CD3-647             CD3                   ‡             BioLegend           300422             UCHT1                     Alexa Fluor 647   AB_493092

  CD3-660             CD3                   ‡             eBioscience         50-0037-41         OKT3                      eFluor 660        AB_2574150

  CD3-APC             CD3                   ‡             eBioscience         17-0038-41         UCHT1                     APC               AB_10804761

  CD45RO-APC          CD45RO                ‡             BioLegend           304210             UCHL1                     APC               AB_314426

  ER-647              ER                    ‡             Abcam               AB205851           EPR4097                   Alexa Fluor 647   

  FOXO3a-647          FOXO3a                ‡             Abcam               AB196539           EP1949Y                   Alexa Fluor 647   

  GZMA-e660           Granzyme A            ‡             ThermoFisher        50-9177-41         CB9                       eFluor 660        AB_2574330

  GZMB-647            Granzyme_B            ‡             BioLegend           515405             GB11                      Alexa Fluor 647   AB_2294995

  GZMB-APC            Granzyme_B            ‡             R and D Systems     IC29051A           356412                    APC               AB_894691

  HER2-647            HER2                  ‡             BioLegend           324412             24D2                      Alexa Fluor 647   AB_2262300

  mCD49b-647          ms_CD49b              ‡             BioLegend           103511             HMα2                      Alexa Fluor 647   AB_528830

  NCAM-647            NCAM/CD56             ‡             BioLegend           362513             5.1H11                    Alexa Fluor 647   AB_2564086

  NCAM-e660           NCAM/CD56             ‡             ThermoFisher        50-0565-80         5tukon56                  eFluor 660        AB_2574160

  pAKT-647            pAKT                  ‡             CST                 4075               D9E                       Alexa Fluor 647   AB_10691856

  pERK-647            pERK (T202/Y204)      ‡             CST                 4375               E10                       Alexa Fluor 647   AB_10706777

  pERK-647            pERK (T202/Y204)      ‡             BioLegend           369503             6B8B69                    Alexa Fluor 647   AB_2571895

  pIKBa-660           pIKBa                 ‡             eBioscience         50-9035-41         RILYB3R                   eFluor 660        AB_2574310

  YAP-647             YAP                   ‡             CST                 38707S             D8H1X                     Alexa Fluor 647   

  anit-FANCD2         FANCD2                ‡             Bethyl              IHC-00624          Polyclonal                N/D               AB_10752755

  anit-pcJUN          p-cJUN                ‡             Santa Cruz          SC-822             KM-1                      N/D               AB_627262

  anti-AXL            AXL                   ‡             CST                 8661               C89E7                     N/D               AB_11217435

  anti-CXCR5          CXCR5                 ‡             GeneTex             GTX100351          Polyclonal                N/D               AB_1240668

  anti-CXCR5          CXCR5                 ‡             R and D             MAB-190-SP         51505                     N/D               AB_2292654

  anti-FOXO3a         FOXO3a                ‡             CST                 2497               75D8                      N/D               AB_836876

  anti-GZMB           Granzyme B            ‡             Abcam               AB4059             Polyclonal                N/D               AB_304251

  anti-PD1            PD-1                  ‡             Abcam               AB63477            Polyclonal                N/D               AB_2159165

  anti-PD1            PD-1                  ‡             ThermoFisher        14-9985-81         J43                       N/D               AB_468663

  anti-PD1            PD-1                  ‡             R and D             AF1021             Polyclonal                N/D               AB_354541

  anti-RFP            RFP                   ‡             ThermoFisher        R10367             Polyclonal                N/D               AB_2315269

  CD11C-BV570         CD11C                 ‡             BioLegend           117331             N418                      BV570             AB_10900261

  CD45-BV785          CD45                  ‡             BioLegend           304047             HI30                      BV785             AB_2563128

  LY6G-BV570          LY6G                  ‡             BioLegend           127629             1A8                       BV570             AB_10899738
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Show positive/correct signals in multiple samples/tissues.

†Show positive/correct signals in some but not all samples tested.

‡Show no signal or incorrect signals in most samples tested.

In the current work, we rely exclusively on commercial antibodies that have previously been validated using IHC or conventional immunofluorescence; when feasible we confirm that staining by t-CyCIF resembles what has previously been reported for IHC staining. This does not constitute a sufficient level of testing or validation for discovery science or clinical studies and the patterns of staining described in this paper should therefore be considered illustrative of the t-CyCIF approach rather than definitive descriptions; we are currently developing a database of matched t-CyCIF and IHC images across multiple tissues and knockdown cell lines to address this issue and share validation test data with the wider research community.

Fluorophore inactivation, cycle count and tissue integrity {#s2-2}
----------------------------------------------------------

The efficiency of fluorophore inactivation by hydrogen peroxide, light and high pH varies with fluorophore but only minimally with the antibody to which the fluorophore is coupled (Alexa Fluor 488 is inactivated more slowly than Alexa Fluor 570 or 647; [Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We typically incubate specimens in bleaching conditions for 60 min, which is sufficient to reduce fluorescence intensity by 10^2^ to 10^3^-fold ([Figure 4C](#fig4){ref-type="fig"}). When testing new antibodies or analyzing new tissues, imaging is performed after each bleaching step and prior to initiation of another t-CyCIF cycle to ensure that fluorophore inactivation is complete. In preliminary studies, we have tested a range of other fluorophores for their compatibility with t-CyCIF including FITC, TRITC, phycoerythrin, Allophycocyanin, eFluor 570 and eFluor 660 (eBioscience). We conclude that it will be feasible to increase the number of t-CyCIF channels per cycle from four to at least six (3 to 5 antibodies plus a DNA stain). However, all the images in this paper are collected using a four-channel method.

![Efficacy of fluorophore inactivation and preservation of tissue integrity.\
(**A**) Exemplary image of a human tonsil stained with PCNA-Alexa 488 that underwent 0, 15, 30 or 60 min of fluorophore inactivation. (**B**) Effect of bleaching duration on the distribution of anti-PCNA-Alexa 488 staining intensities for samples used in (**A**). The distribution is computed from mean values for the fluorescence intensities across all cells in the image that were successfully segmented. The gray band denotes the range of background florescence intensities (below 6.2 in log scale). (**C**) Effect of bleaching duration on mean intensity for nine antibodies conjugated to Alexa fluor 488, efluor 570 or Alexa fluor 647. Intensities were determined as in (**B**). The gray band denotes the range of background florescence intensities. (**D**) Impact of t-CyCIF cycle number on tissue integrity for four exemplary tissue cores. Nuclei present in the first cycle are labeled in red and those present after the 10th cycle are in green. The numbers at the bottom of the images represent nuclear counts in cycle 1 (red) and cycle 10 (green), respectively. (**E**) Impact of t-CyCIF cycle number on the integrity of a TMA containing 48 biopsies obtained from 16 different healthy and tumor tissues (see Materials and methods for TMA details) stained with 10 rounds of t-CyCIF. The number of nuclei remaining in each core was computed relative to the starting value; small fluctuations in cell count explain values \> 1.0 and arise from errors in image segmentation. Data for six different breast cores is shown to the right. (**F**) Nuclear staining of a melanoma specimen subjected to 20 cycles of t-CyCIF emphasizes the preservation of tissue integrity (22 ± 4%). (**G**) Selected images of the specimen in (**F**) from cycles 0, 5, 15 and 20.\
10.7554/eLife.31657.014Figure 4---source data 1.Mean intensity versus bleach time for multiple antibodies ([Figure 4C](#fig4){ref-type="fig"}).\
10.7554/eLife.31657.015Figure 4---source data 2.Intensity distribution for single cells versus bleach time for one antibody ([Figure 4B](#fig4){ref-type="fig"}).\
10.7554/eLife.31657.016Figure 4---source data 3.Cell counts dependent on number of staining cycles ([Figure 4E](#fig4){ref-type="fig"}).](elife-31657-fig4){#fig4}

The primary limitation on the number of t-CyCIF cycles that can be performed is the integrity of the tissue: some tissues samples are physically more robust and can withstand more staining and washing procedures than others ([Figure 4D](#fig4){ref-type="fig"}). To study the effect of cycle number on tissue integrity, we performed a 10-cycle t-CyCIF experiment on a tissue microarray (TMA) comprising a total of 40 cores from 16 different tissues and tumor types. After each t-CyCIF cycle, the number of nuclei remaining was quantified for each core relative to the initial number. For example, [Figure 4D](#fig4){ref-type="fig"} shows breast, bladder, lung and prostate cores in which cell number was reduced after 10 cycles by \~2% and an unusually high 46% (apparent increases in cell number in these data are caused by fluctuation in the performance of cell segmentation routines and are not statistically significant). Cells that were lost appear red in these images. The data show that cell loss is often uneven across samples, preferentially affecting regions of tissue with low cellularity.

Overall, we found that the extent of cell loss varied with tissue type and, within a single tissue type, from core to core (six breast cores are shown; [Figure 4E](#fig4){ref-type="fig"}). For many tissues, we have not yet attempted to optimize cycle number and the experiments performed to date do not fully control for pre-analytical variables ([@bib52]) such as fixation time and the age of tissue blocks. As a rule, we find that normal tonsil, skin, glioblastoma, ovarian cancer, pancreatic cancer and melanoma can be subjected to \>15 cycles with less than 25% cell loss. [Figure 4F](#fig4){ref-type="fig"} shows a melanoma specimen subjected to 20 t-CyCIF cycles with good preservation of cell and tissue morphology ([Figure 4G](#fig4){ref-type="fig"}). We conclude that t-CyCIF is compatible with multiple normal tissues and tumor types but that some tissues and/or specimens can be subjected to more cycles than others. One requirement for high cycle number appears to be cellularity: samples in which cells are very sparse tend to be more fragile. We expect improvements in cycle number with additional experimentation and the use of fluidic devices that deliver staining and wash liquids more gently.

One potential concern about cyclic immunofluorescence is that the process is relatively slow; each cycle takes 6--8 hr and we typically perform one cycle per day. However, a single operator can easily process 30 slides in parallel, and in the case of TMAs, 30 slides can comprise over 2000 different samples. Under these conditions, the most time-consuming step in t-CyCIF is collecting the 200--400 fields of view needed to image each slide. Time could be saved by imaging fewer cells per sample, but the results described below (demonstrating substantial cellular heterogeneity in a single piece of a tumor resection) strongly argue in favor of analyzing as large a fraction of each tissue specimen as possible. As a practical matter, data analysis and data interpretation remain more time-consuming than data collection. We also note that the throughput of t-CyCIF compares favorably with other tissue-imaging platforms or single-cell transcriptome profiling.

Impact of cycle number on immunogenicity {#s2-3}
----------------------------------------

Because t-CyCIF assembles multiplex images sequentially, it is sensitive to factors that alter immunogenicity as cycle number increases. To investigate such effects, we performed a 16-cycle t-CyCIF experiment in which the order of antibody addition was varied between two immediately adjacent tissue slices cut from the same tissue block ([Figure 5A](#fig5){ref-type="fig"}; Slides A and B); the study was repeated three times, once with tonsil and twice with melanoma specimens with similar results (\~1.8 × 10^5^ cells were used for the analysis and overall cell loss was \<15%).

![Design of a 16-cyle experiment used to assess the reliability of t-CyCIF data.\
(**A**) t-CyCIF experiment involving two immediately adjacent tissue slices cut from the same block of tonsil tissue (Slide A and Slide B). The antibodies used in each cycle are shown (antibodies are described in [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Highlighted in blue are cycles in which the same antibodies were used on slides A and B at the same time to assess reproducibility. Highlighted in yellow are cycles in which antibodies targeting PCNA, Vimentin and Tubulin were used repeatedly on both slides A and B to assess repeatability. Blue arrows connecting Slides A and B show how antibodies were swapped among cycles. (**B**) Representative images of Slide A (top panels) and Slide B specimens (bottom panels) after each t-CyCIF cycle. The color coding highlighting specific cycles is the same as in A.](elife-31657-fig5){#fig5}

This experiment made it possible to judge: (i) the repeatability of staining a single specimen using the same set of antibodies ([Figure 5A](#fig5){ref-type="fig"}, denoted by yellow highlight) (ii) the similarity of staining between slides A and B (blue highlight) and (iii) the effect of swapping the order of antibody addition (cycle number) between slides A and B (blue lines). Comparisons within a single slide were made on a cell-by-cell basis but because slides A and B contain different cells, comparisons between slides were made at the level of intensity distributions (computed on a per-cell basis following segmentation). The repeatability of staining (as measured in cycles 3, 7, 12 and 16) was performed using anti-PCNA-Alexa 488, anti-Vimentin-Alexa 555 and anti-Tubulin- Alexa 647 which bind abundant proteins with distrinct cellular distributions ([Figure 5B](#fig5){ref-type="fig"}). Repeated staining of the same antigen is expected to saturate epitopes, but we reasoned that this effect would be less pronounced the more abundant the antigen. For PCNA, the correlation in staining intensities across four cycles was high (ρ = 0.95 to 0.99) and somewhat lower in the case of Vimentin and Tubulin (ρ = 0.80 to 0.95; [Figure 6A](#fig6){ref-type="fig"}; a more extensive comparison is shown in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). When we examined the corresponding images, it was readily apparent that Tubulin, and to a lesser extent Vimentin, stained more intensely in later than in earlier t-CyCIF cycles (see intensity distributions in [Figure 6A](#fig6){ref-type="fig"} and images in [Figure 6B](#fig6){ref-type="fig"}). When images were scaled to equalize the intensity range (by histogram equalization), staining patterns were indistinguishable across all cycles and loss of cells or specific subcellular structures was not obviously a factor ([Figure 6B](#fig6){ref-type="fig"}, left vs right panels and [Figure 6C](#fig6){ref-type="fig"}). Thus, for at least a subset of antibodies, staining intensity increases rather than decreases with cycle number whereas background fluorescence falls. As a consequence, dynamic range, defined here as the ratio of the least to the most intense 5% of pixels, frequently increases with cycle number ([Figure 6A](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). These effects were reproducible across slides A and B in all three experiments performed.

![Impact of cycle number on repeatability, reproducibility and strength of t-CyCIF immuno-staining.\
(**A**) Plots on left: comparison of staining intensity for anti-PCNA Alexa 488 (top), anti-vimentin Alexa 555 (middle) and anti-tubulin Alexa 647 (bottom) in cycle 3 vs. 16 and cycle 7 vs. 12 of the 16-cycle t-CyCIF experiment show in [Figure 5](#fig5){ref-type="fig"}. Intensity values were integrated across whole cells and the comparison is made on a cell-by-cell basis. Spearman's correlation coefficients are shown. Plots in middle: intensity distributions at cycles 3 (blue), 7 (yellow), 12 (red) and 16 (green); intensity values were integrated across whole cells to construct the distribution. Box plots to right: estimated dynamic range at four cycle numbers 3, 7, 12, 16. Red lines denote median intensity values (across 56 frames), boxes denote the upper and lower quartiles, whiskers indicate values outside the upper/lower quartile within 1.5 standard deviations, and red dots represent outliers. (**B**) Representative images showing anti-tubulin Alexa 647 staining at four t-CyCIF cycles; original images are shown on the left (representing the same exposure time and approximately the same illumination) and images scaled by histogram equalization to similar intensity ranges are shown on the right. (**C**) Image for anti-CD45RO-Alexa 555 at cycles 5 and 15 scaled to similar intensity ranges as described in (**B**); the dynamic range (DR) of the cycle 15 image is \~3.3 fold lower than that of the Cycle 5 image, but shows similar morphology. (**D**) Intensity distributions for selected antibodies that were used in different cycles on Slides A and B. Colors denote the degree of concordance between the slides ranging from high (overlap \>0.8 in yellow; PCNA), slightly increased or decreased with increasing cycle (overlap 0.6 to 0.8 in light blue or light red; S100 and SMA) or substantially increased or decreased (overlap \<0.6 in red or blue; VEGFR2 and CD45RO). (**E**) Summary of effects of cycle number on antibody staining based on the degree of overlap in intensity distributions (the overlap integral); color coding is the same as in (**D**). (**F**) Effect of cycle number and specimen identity on overlap integrals for all antibodies and all cycles assayed. The red line denotes the median intensity value, boxes denote the upper/lower quartiles, and whiskers indicate values outside the upper/lower quartile and within 1.5 standard deviations, and red dots represent outliers. All the numeric data in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} are available in a Jupyter notebook; see Code Availability section of Materials and methods for details.\
10.7554/eLife.31657.020Figure 6---source data 1.Single-cell intensity data used in [Figure 6](#fig6){ref-type="fig"}.](elife-31657-fig6){#fig6}

When we compared staining between slides A and B for the same antibodies and cycle number, the overlap in intensity distributions was high (\>0.85), demonstrating good sample to sample reproducibility ([@bib59]). The overlap remained high for the majority of antibodies even when they were used in different cycles on slides A and B, but for some antibodies, signal intensity clearly increased or decreased with cycle number ([Figure 6D](#fig6){ref-type="fig"}; blue and red outlines). In the case of eight antibodies for which the effect of cycle number was greatest (including tubulin, as discussed above), the overlap in intensity distributions was \<0.6 as a consequence of both increases and decreases in staining intensity ([Figure 6E](#fig6){ref-type="fig"}). Overall, we found that the repeatability of staining between two biological samples was highest when the antibodies were used in the same cycle on both samples, lower when the antibodies were used in different cycles on the sample, and lowest when both the order and sample were different ([Figure 6F](#fig6){ref-type="fig"}).

The reasons for changes in staining intensity with cycle number are not known, but the fact that the same changes were observed across multiple experiments (for any single antibody) suggests that they arise not from irreproducibility of the t-CyCIF procedure but rather from changes in epitope accessibility. Even in these cases, it appears that it is absolute intensity rather than morphology that is variable. Thus, while changes in staining intensity with cycle number are a concern for a subset of t-CyCIF antibodies, it should be possible to minimize the problem by staining all samples in the same order. Other approaches will also be important; for example, using calibration standards and identifying antibodies exhibiting the least variation with cycle number.

One way to reduce artefacts generated by differences in the order of antibody addition is to create a single high-plex antibody mixture and then stain all antigens in parallel. This approach is not compatible with t-CyCIF but is feasible using methods such as MIBI or CODEX ([@bib2]; [@bib17]). However, there is substantial literature showing that the formulation of highly multiplex immuno-assays is complicated by interaction among antibodies ([@bib12]) that has a physicochemical explanation in some cases in weak self-association and viscosity ([@bib55]). Consistent with these data, we have observed that when eight or more unlabeled antibodies are added to a t-CyCIF experiment, the intensity of staining can fall, although the effect is smaller than observed with antibodies most sensitive to order of addition. We conclude that the construction of sequentially applied t-CyCIF antibody panels and of single high-plex mixtures will both require optimization of specific panels and their method of use.

Analysis of large specimens by t-CyCIF {#s2-4}
--------------------------------------

Review of large histopathology specimens by pathologists involves rapid and seamless switching between low-power fields to scan across large regions of tissue and high-power fields to study cellular morphology. To mimic this integration of information at both tissue and cellular scales, we performed eight-cycle t-CyCIF on a large 2 × 1.5 cm resection specimen that includes pancreatic ductal adenocarcinoma (PDAC) and adjacent normal pancreatic tissue and small intestine ([Figure 7A--C](#fig7){ref-type="fig"}). Nuclei were located in the DAPI channel and cell segmentation performed using a watershed algorithm ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}: see Materials and methods section for a discussion of the method and its caveats) yielding \~2 × 10^5^ single cells each associated with a vector comprising 25 whole-cell fluorescence intensities. Differences in subcellular distribution were evident for many proteins, but for simplicity, we only analyzed fluorescence intensity on a per-antigen basis integrated over each whole cell. Results were visualized by plotting intensity value onto the segmentation data ([Figure 7D](#fig7){ref-type="fig"}), by computing correlations on a cell-by-cell basis ([Figure 7E](#fig7){ref-type="fig"}), or by using t-distributed stochastic neighbor embedding (t-SNE) ([@bib29]), which clusters cells in 2D based on their proximity in the 25-dimensional space of image intensity data ([Figure 8A](#fig8){ref-type="fig"}).

![t-CyCIF of a large resection specimen from a patient with pancreatic cancer.\
(**A**) H&E staining of pancreatic ductal adenocarcinoma (PDAC) resection specimen that includes portions of cancer and non-malignant pancreatic tissue and small intestine. (**B**) The entire sample comprising 143 stitched 10X fields of view is shown. Fields that were used for downstream analysis are highlighted by yellow boxes. (**C**) A representative field of normal intestine across 8 t-CyCIF rounds; see [Supplementary file 3](#supp3){ref-type="supplementary-material"} for a list of antibodies. (**D**) Segmentation data for four antibodies; the color indicates fluorescence intensity (blue = low, red = high). (**E**) Quantitative single-cell signal intensities of 24 proteins (rows) measured in \~4×10^3^ cells (columns) from panel (**C**). The Pearson correlation coefficient for each measured protein with E-cadherin (at a single-cell level) is shown numerically. Known dichotomies are evident such as anti-correlated expression of epithelial (E-Cadherin) and mesenchymal (Vimentin) proteins. Proteins highlighted in red are further analyzed in [Figure 8](#fig8){ref-type="fig"}.\
10.7554/eLife.31657.023Figure 7---source data 1.Single-cell intensity data used in [Figure 7E](#fig7){ref-type="fig"}.\
10.7554/eLife.31657.024Figure 7---source data 2.Single-cell intensity data used in [Figures 7](#fig7){ref-type="fig"} and [8](#fig8){ref-type="fig"}.](elife-31657-fig7){#fig7}

![High-dimensional single-cell analysis of human pancreatic cancer sample with t-CyCIF.\
(**A**) t-SNE plots of cells derived from small intestine (left) or the PDAC region (right) of the specimen shown in [Figure 7](#fig7){ref-type="fig"} with the fluorescence intensities for markers of proliferation (PCNA and Ki67) and signaling (pERK and β-catenin) overlaid on the plots as heat maps. In both tissue types, there exists substantial heterogeneity: circled areas indicate the relationship between pERK and β-catenin levels in cells and represent positive ('a'), negative ('b') or no association ('c') between these markers. (**B**) Representative frames of normal pancreas and pancreatic ductal adenocarcinoma from the 8-cycle t-CyCIF staining of the same resection specimen from [Figure 7](#fig7){ref-type="fig"}. (**C**) t-SNE representation and clustering of single cells from normal pancreatic tissue (red), small intestine (blue) and pancreatic cancer (green). Projected onto the origin of each cell in t-SNE space are intensity measures for selected markers demonstrating distinct staining patterns. (**D**) Fluorescence intensity distributions for selected markers in small intestine, pancreas and PDAC.\
10.7554/eLife.31657.026Figure 8---source data 1.Single-cell data in FCS format ([Figure 8C--E](#fig8){ref-type="fig"}).](elife-31657-fig8){#fig8}

The analysis in [Figure 7E](#fig7){ref-type="fig"} shows that E-cadherin, keratin and β-catenin levels are highly correlated with each other, whereas vimentin and VEGFR2 receptor levels are anti-correlated, recapitulating the known dichotomy between epithelial and mesenchymal cell states in normal and diseased tissues. Many other physiologically relevant correlations are also observed, for example between the levels of pERK^T202/Y204^ (the phosphorylated, active form of the kinase) and activating phosphorylation of the downstream kinase pS6^S235/S236^ (r = 0.81). When t-SNE was applied to all cells in the specimen, we found that those identified during histopathology review as being from non-neoplastic pancreas (red) were distinct from PDAC (green) and also from the neighboring non-neoplastic small intestine (blue) ([Figure 8B--D](#fig8){ref-type="fig"}). Vimentin and E-Cadherin had very different levels of expression in PDAC and normal pancreas as a consequence of epithelial-to-mesenchymal transitions (EMT) in malignant tissues as well as the presence of a dense tumor stroma, a desmoplastic reaction that is a hallmark of the PDAC microenvironment ([@bib30]). The microenvironment of PDAC was more heavily infiltrated with CD45^+^ immune cells than the normal pancreas, and the intestinal mucosa of the small intestine was also replete with immune cells, consistent with the known architecture and organization of this tissue.

The capacity to image samples that are several square centimeters in area with t-CyCIF can facilitate the detection of signaling biomarker heterogeneity. The WNT pathway is frequently activated in PDAC and is important for oncogenic transformation of gastrointestinal tumours ([@bib24]). Approximately 90% of sporadic PDACs also harbor driver mutations in KRAS, activating the MAPK pathway and promoting tumourigenesis ([@bib54]). Studies comparing these pathways have come to different conclusions with respect to their relationship: some studies show concordant activation of MAPK and WNT signaling and others argue for exclusive activation of one pathway or the other ([@bib23]). In t-SNE plots derived from images of PDAC, multiple sub-populations of cells representing negative, positive or no correlation between pERK and β-catenin levels can be seen (marked with labels 'a', 'b' or 'c', respectively in [Figure 8A](#fig8){ref-type="fig"}). The same three relationships can be found in non-neoplastic pancreas and small intestine ([Figures 8A](#fig8){ref-type="fig"} and [7C](#fig7){ref-type="fig"}). In PDAC, malignant cells can be distinguished from stromal cells, to a first approximation, by high proliferative index, which can be measured by staining for Ki-67 and PCNA ([@bib5]). When we gated for cells that were both Ki67^high^ and PCNA^high^, and thus likely to be malignant, the co-occurrence of different relationship between pERK and β-catenin levels on a cellular level was again evident. While we cannot exclude the possibility of phospho-epitope loss during sample preparation, it appears that the full range of possible relationships between the MAPK and WNT signaling pathways described in the literature can be found within a specimen from a single patient, illustrating the impact of tissue context on the activities of key signal transduction pathways.

Multiplex imaging of immune infiltration {#s2-5}
----------------------------------------

Immuno-oncology drugs, including immune checkpoint inhibitors targeting CTLA-4 and the PD-1/PD-L1 axis are rapidly changing the therapeutic possibilities for traditionally difficult-to-treat cancers including melanoma, renal and lung cancers, but responses are variable across and within cancer types. The hope is that tumor immuno-profiling will yield biomarkers predictive of therapeutic response in individual patients. For example, expression of PD-L1 correlates with responsiveness to the ICIs pembrolizumab and nivolumab ([@bib31]) but the negative predictive value of PD-L1 expression alone is insufficient to stratify patient populations ([@bib43]). In contrast, by measuring PD-1, PD-L1, CD4 and CD8 by IHC on sequential tumor slices, it has been possible to identify some immune checkpoint inhibitor-responsive melanom patients ([@bib49]). To test t-CyCIF in this application, eight-cycle imaging was performed on a 1 × 2 cm specimen of clear-cell renal cell carcinoma using 10 antibodies against multiple immune markers and 12 against other proteins expressed in tumor and stromal cells ([Figure 9A--B](#fig9){ref-type="fig"}; [Supplementary file 4](#supp4){ref-type="supplementary-material"}). A region of the specimen corresponding to tumor was readily distinguishable from non-malignant stroma based on α-SMA expression (α-SMA^high^ regions denote stroma and α-SMA^low^ regions high density of malignant cells).

![Spatial distribution of immune infiltrates and checkpoint proteins.\
(**A**) Low-magnification image of a clear cell renal cancer subjected to 12-cycle t-CyCIF (see [Supplementary file 4](#supp4){ref-type="supplementary-material"} for a list of antibodies). Regions high in α-smooth muscle actin (α-SMA) correspond to stromal components of the tumor, those low in α-SMA represent regions enriched for malignant cells. (**B**) Representative images from selected t-CyCIF channels are shown. (**C**) Quantitative assessment of total lymphocytic cell infiltrates (CD3^+^ cells), CD8^+^ T lymphocytes, cells expressing PD-1 or its ligand PD-L1 or the VEGFR2 for the entire tumor or for α-SMA^high^ and α-SMA^low^ regions. VEGFR2 is a protein primarily expressed in endothelial cells and is targeted in the treatment of renal cell cancer. The error bars represent the S.E.M. derived from 100 rounds of bootstrapping. (**D**) Density plot for CD3 and CD8 expression on single cells in the tumor (left) or stromal domains (right). (**E**) Centroids of CD3^+^ or CD3^+^CD8^+^ cells in blue or dark blue as well as cells staining as SMA^high^ or SMA^low^ (gray and light-gray, respectively) used to define the stromal and tumor regions. ([**F**]{.smallcaps}) Centroids of PD-1^+^ and PD-L1^+^ cells are shown in red and green, respectively. (**G**) Results of a K-nearest neighbor algorithm used to compute areas in which PD-1^+^ and PD-L1^+^ cells lie within \~10 µm of each other and with high spatial density (in yellow) and thus, are potentially positioned to interact at a molecular level.\
10.7554/eLife.31657.029Figure 9---source data 1.Immune cell counts from bootstrapping in tumor and stroma regions ([Figure 9C](#fig9){ref-type="fig"}).\
10.7554/eLife.31657.030Figure 9---source data 2.Single-cell intensity data used in [Figure 9](#fig9){ref-type="fig"}.](elife-31657-fig9){#fig9}

In the α-SMA^low^ domain, CD3^+^ or CD8^+^ lymphocytes were fourfold enriched ([Figure 9C](#fig9){ref-type="fig"}) and PD-1 and PD-L1-positive cells were 13 to 20-fold more prevalent as compared to the surrounding tumor stroma (α-SMA^high^ domain); CD3^+^ CD8^+^ double positive T-cells were found almost exclusively in the tumor. Suppression of immune cells is mediated by binding of PD-L1 ligand, which is commonly expressed by tumor cells, to the PD1 receptor expressed on immune cells ([@bib49]). To begin to estimate the likelihood of ligand-receptor interactions, we quantified the degree of co-localization of cells expressing the two molecules. The centroids of PD-1^+^ or PD-L1^+^ cells were determined from images (PD-1, red; PD-L1, green, [Figure 9E](#fig9){ref-type="fig"}) and co-localization (highlighted in yellow, [Figure 9F](#fig9){ref-type="fig"}) computed by k-nearest neighbor analysis. We found that co-localization of PD-1/PD-L1 was \~2.7-fold more likely ([Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}) in tumor and stroma and was concentrated on the tumor-stroma border consistent with previous reports on melanoma ([@bib49]). These data demonstrate the potential of spatially resolved immuno-phenotyping to quantify state and location of tumor infiltrating lymphocytes; such data may ultimately yield biomarkers predictive of sensitivity to immune checkpoint inhibitor ([@bib49]).

Analysis of diverse tumor types and grades using t-CyCIF of tissue-microarrays (TMA) {#s2-6}
------------------------------------------------------------------------------------

To explore the general utility of t-CyCIF in a range of healthy and cancer tissues we applied eight cycle t-CyCIF to TMAs containing 39 different biopsies from 13 healthy tissues and 26 biopsies corresponding to low- and high-grade cancers from the same tissue types ([Figure 10A](#fig10){ref-type="fig"} and [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}, [Supplementary file 3](#supp3){ref-type="supplementary-material"} for antibodies used, [Supplementary file 5](#supp5){ref-type="supplementary-material"} for TMA details and naming conventions) and then performed t-SNE and clustering on single-cell intensity data ([Figure 10B](#fig10){ref-type="fig"}). The great majority of TMA samples mapped to one or a few discrete locations in the t-SNE projection (compare normal kidney tissue - KI1, low-grade tumors - KI2, and high-grade tumors -- KI3; [Figure 10C](#fig10){ref-type="fig"}), although ovarian cancers were scattered across the t-SNE projection ([Figure 10D](#fig10){ref-type="fig"}); overall, there was no separation between normal tissue and tumors regardless of grade ([Figure 10E](#fig10){ref-type="fig"}). In a number of cases, high-grade cancers from multiple different tissues of origin co-clustered, implying that transformed morphologies and cell states were closely related. For example, while healthy and low-grade pancreatic and stomach cancer occupied distinct t-SNE domains, high-grade pancreatic and stomach cancers were intermingled and could not be readily distinguished ([Figure 10F](#fig10){ref-type="fig"}), recapitulating the known difficulty in distinguishing high-grade gastrointestinal tumors of diverse origin by histophathology ([@bib51]). Nonetheless, t-CyCIF might represent a means to identify discriminating biomarkers by efficiently sorting through large numbers of alternative antigens and antigen localizations.

![Eight-cycle t-CyCIF of a tissue microarray (TMA) including 13 normal tissues and corresponding tumor types.\
The TMA includes normal tissue types, and corresponding high- and low-grade tumors, for a total of 39 specimens (see [Supplementary file 3](#supp3){ref-type="supplementary-material"} for antibodies and [Supplementary file 5](#supp5){ref-type="supplementary-material"} for specifications of the TMA). (**A**) Selected images of different tissues illustrating the quality of t-CyCIF images (additional examples shown in [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"}; full data available online at [www.cycif.org](http://www.cycif.org)). (**B**) t-SNE plot of single-cell intensities of all 39 cores; data were analyzed using the CYT package (see Materials and methods). Tissues of origin and corresponding malignant lesions were labeled as follows: BL, bladder cancer; BR, breast cancer CO, Colorectal adenocarcinoma, KI, clear cell renal cancer, LI, hepatocellular carcinoma, LU, lung adenocarcinoma, LY, lymphoma, OV, high-grade serous adenocarcinoma of the ovary, PA, pancreatic ductal adenocarcinoma, PR, prostate adenocarcinoma, UT, uterine cancer, SK, skin cancer (melanoma), ST, stomach (gastric) cancer. Numbers refer to sample type; '1' to normal tissue, '2' to -grade tumors and '3' to high-grade tumors. (**C**) Detail from panel B of normal kidney tissue (KI1) a low-grade tumor (KI2) and a high-grade tumor (KI3) (**D**) Detail from panel B of normal ovary (OV1) low-grade tumor (OV2) and high-grade tumor (OV3). (**E**) t-SNE plot from Panel B coded to show the distributions of all normal, low-grade and high-grade tumors. (**F**) tSNE clustering of normal pancreas (PA1) and pancreatic cancers (low-grade, PA2, and high-grade, PA3) and normal stomach (ST1) and gastric cancers (ST2 and ST3, respectively) showing intermingling of high-grade cells.\
10.7554/eLife.31657.033Figure 10---source data 1.Single-cell intensity data used in [Figure 10](#fig10){ref-type="fig"}.](elife-31657-fig10){#fig10}

Quantitative analysis reveals global and regional heterogeneity and multiple histologic subtypes within the same tumor in glioblastoma multiforme (GBM) {#s2-7}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Data from single-cell genomics reveals extensive heterogeneity in many types of cancer ([@bib50]) but our understanding of this phenomenon requires spatially resolved data ([@bib16]). We performed eight-cycle imaging on a 2.5 cm x 1.8 mm resected glioblastoma (GBM) specimen imaging markers of neural development, cell cycle state and signal transduction ([Figure 11A--B](#fig11){ref-type="fig"}, [Supplementary file 6](#supp6){ref-type="supplementary-material"}). GBM is a highly aggressive and genetically heterogeneous ([@bib6]) brain cancer commonly classified into four histologic subtypes ([@bib35]). Following image segmentation, phenotypic heterogeneity was assessed at three spatial scales corresponding to: (i) 1.6 × 1.4 mm fields of view (252 total) each of which comprised 10^3^ to 10^4^ cells (ii) seven macroscopic regions of \~10^4^ to 10^5^ cells each, corresponding roughly to tumor lobes and (iii) the whole tumor comprising \~10^6^ cells. To quantify local heterogeneity, we computed the informational entropy on a-per-channel basis for 10^3^ randomly selected cells in each field ([Figure 11C](#fig11){ref-type="fig"}; see online Materials and methods for details). In this setting, informational entropy is a measure of cell-to-cell heterogeneity on a mesoscale corresponding to 10--30 cell diameters. For a marker such as EGFR, which can function as a driving oncogene in GBM, informational entropy was high in some areas ([Figure 11C](#fig11){ref-type="fig"}; red dots) and low in others (blue dots). Areas with high entropy in EGFR abundance did not co-correlate with areas that were most variable with respect to a downstream signaling protein such as pERK. Thus, the extent of local heterogeneity varied with the region of the tumor and the marker being assayed.

![Molecular heterogeneity in a single GBM tumor.\
(**A**) Representative low-magnification image of a GBM specimen generated from 221 stitched 10X frames; the sample was subjected to 10 rounds of t-CyCIF using antibodies listed in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. (**B**) Magnification of frame 152 (whose position is marked with a white box in panel A) showing staining of pERK, pRB and EGFR; lower panel shows a further magnification to allow single cells to be identified. (**C**) Normalized Shannon entropy of each of 221 fields of view to determine the extent of variability in signal intensity for 1000 cells randomly selected from that field for each of the antibodies shown. The size of the circles denotes the number of cells in the field and the color represents the value of the normalized Shannon entropy (data are shown only for those fields with more than 1000 cells; see Materials and methods for details).\
10.7554/eLife.31657.035Figure 11---source data 1.Normalized entropy data shown in [Figure 11C](#fig11){ref-type="fig"}.\
10.7554/eLife.31657.036Figure 11---source data 2.Single-cell intensity data used in [Figure 11](#fig11){ref-type="fig"} and [12](#fig12){ref-type="fig"}.](elife-31657-fig11){#fig11}

Semi-supervised clustering using expectation--maximization Gaussian mixture (EMGM) modeling of all cells in the tumor yielded eight distinct clusters, four of which encompassed 85% of all cells ([Figure 12A](#fig12){ref-type="fig"} and [Figure 12---figure supplement 1](#fig12s1){ref-type="fig"}). Among these, cluster one had high EGFR levels, cluster two had high NGFR and Ki67 levels and cluster six had high levels of vimentin; cluster five was characterized by high keratin and pERK levels. The presence of four highly populated t-CyCIF clusters is consistent with data from single-cell RNA-sequencing of \~400 cells from five GBMs ([@bib36]). Three of the t-CyCIF clusters have properties reminiscent of established histological subtypes including: classical, cluster 1; pro-neural, cluster 3; and mesenchymal, cluster 6, but additional work will be required to confirm such assignments.

![Spatial distribution of molecular phenotypes in a single GBM.\
(**A**) Clustering of intensity values for 30 antibodies in a 10-cycle t-CyCIF analysis integrated over each whole cell based on images shown in [Figure 11](#fig11){ref-type="fig"}. Intensity values were clustered using expected-maximization with Gaussian mixtures (EMGM), yielding eight clusters, of which four clusters accounted for the majority of cells. The intensity scale shows the average level for each intensity feature in that cluster. The number of cells in the cluster is shown as a percentage of all cells in the tumor (bottom of panel). An analogous analysis is shown for 12 clusters in [Figure 12---figure supplement 2](#fig12s2){ref-type="fig"}. ([**B**]{.smallcaps}) EMGM clusters (in color code) mapped back to the positions of individual cells in the tumor. The coordinate system is the same as in [Figure 11A](#fig11){ref-type="fig"}. The positions of seven macroscopic regions (R1-R7) representing distinct lobes of the tumor are also shown. (**C**) Magnified view of Frame 147 from region R5 with EMGM cluster assignment for each cell in the frame; dots represent the centroids of single cells. (**D**) The proportional representation of EMGM clusters in each tumor region as defined in panel (**B**).\
10.7554/eLife.31657.040Figure 12---source data 1.Ratios of EMGM clusters in different regions of a GBM ([Figure 12D](#fig12){ref-type="fig"}).](elife-31657-fig12){#fig12}

To study the relationship between phenotypic diversity and tumor architecture, we mapped each cell to an EMGM cluster (denoted by color). Extensive intermixing was observed at all spatial scales ([Figure 12B](#fig12){ref-type="fig"}). For example, field of view 147 was highly enriched for cells corresponding to cluster 5 (yellow), but a higher magnification view revealed extensive intermixing of four other cluster types on a scale of \~3--5 cell diameters ([Figure 12C](#fig12){ref-type="fig"}). At the level of larger, macroscopic tumor regions, the fraction of cells from each cluster also varied dramatically ([Figure 12D](#fig12){ref-type="fig"}). None of these findings was substantially different when the number of clusters was set to 12 ([Figure 12---figure supplement 2](#fig12s2){ref-type="fig"}).

These results have several implications. First, they suggest that GBM is phenotypically heterogeneous on a spatial scale of 5--1000 cell diameters and that cells corresponding to distinct t-CyCIF clusters are often found in the vicinity of each other. Second, sampling a small region of a large tumor has the potential to misrepresent the proportion and distribution of tumor subtypes, with implications for prognosis and therapy. Similar concepts likely apply to other tumor types with high genetic heterogeneity, such as metastatic melanoma ([@bib47]), and are therefore relevant to diagnostic and therapeutic challenges arising from tumor heterogeneity.

Discussion {#s3}
==========

The complex molecular biology and spatial organization of tissues and solid tumors poses a scientific and diagnostic challenge that is not sufficiently addressed using single-cell genomics, in which morphology is commonly lost, or H&E and single-channel IHC staining, which provide data on only a few proteins or molecular features. At the same time, the vast number of FFPE histological specimens collected in the course of routine clinical care and clinical trials (and in the study of model organisms) represents an underutilized resource with great potential for novel discovery. A variety of methods for performing highly multiplexed immune-based imaging of cells and tissues has recently been described including imaging cytometry ([@bib16]), MIBI ([@bib2]), DNA-exchange imaging (DEI) ([@bib57]) and CODEX ([@bib17]); FISSEQ ([@bib26]) directly images expressed RNAs. Like traditional antibody stripping approaches, the cyclic immunofluorescence approach first described by Gerdes et al ([@bib14]) and further developed here assembles highly multiplexed images by sequential acquisition of lower dimensional immunofluorescence images. We show here that the t-CyCIF implementation of cyclic immunofluorescence is compatible with a wide range of antibodies and tissue types and yields up to 60-plex images with excellent preservation of small intracellular structures.

The requirement in t-CyCIF for multiple rounds of staining and imaging might seem to be a liability but it has several substantial advantages relative to all-in-one methods such as MIBI, DEI and CODEX. First, t-CyCIF can be performed using existing fluorescence microscopes. Not only does this reduce costs and barriers to entry, it allows the unique strengths of slide-scanning, confocal, and structured illumination microscopes to be exploited. Using different instruments, samples several square centimeters in area can be rapidly analyzed at resolutions of \~1 µm and selected fields of view studied at super-resolution (\~110 nm on an OMX Blaze). Multiscale imaging makes it possible to combine tissue-level architecture with subcellular morphology, much like a pathologist switching between low- and high-power fields, but there is little chance that such capabilities can be combined in a single instrument. Because no spectral deconvolution is required, t-CyCIF can use highly optimized filter sets and fluorophores, resulting in good sensitivity. t-CyCIF antibody panels are also simple to assemble and validate using commercial antibodies, including those that constitute FDA-approved diagnostics. This avoids the limitations of an exlusive reliance on pre-assembled reagent kits provided by manufacturers. Finally, t-CyCIF is compatible with H&E staining, enabling fluorescence imaging to be combined with conventional histopathology review.

Commercial systems for non-optical tissue imaging are only now starting to appear and it is difficult to compare their performance to multiplexed immunofluorescence, particularly because the approach published by [@bib14]) is proprietary and available only as commercial service. In contrast, the t-CyCIF method described here can easily be implemented in a conventional research or clinical laboratory without the need for expensive equipment or specialized reagents. As MIBI, DEI and CODEX instruments come on-line, direct comparison with t-CyCIF will be possible. We anticipate that high resolution and good linearity will be areas in which fluorescence imaging is superior to enzymatic amplification, laser ablation or mechanical picking of tissues. t-CyCIF is relatively slow when performed on a single sample, but when many large specimens or TMAs are processed in parallel, throughput is limited primarily by imaging acquisition, which is at least as fast as approaches involving laser ablation. Considerable opportunity exists for further improvement in t-CyCIF by switching from four to six-channels per cycle, optimizing bleach and processing solutions to preserve tissue integrity, using fluidic devices to rapidly process many slides in parallel and developing better software for identifying fields of view that can be skipped in large irregular specimens. Because direct fluorescence will remain challenging in the case of very rare epitopes, we speculate that hybrid approaches involving t-CyCIF and methods such as DEI or CODEX will ultimately prove to be most effective.

As in all methods involving immune detection, antibodies are the most critical and difficult to validate reagents in t-CyCIF. To date, we have shown that over 200 commercial antibodies are compatible with the method as judged by patterns of staining similar to those previously reported for IHC; this is an insufficient level of validation for most studies and we are therefore working to develop a generally useful antibody validation resource ([www.cycif.org](http://www.cycif.org)). Thus, while this paper describes markers relevant to diagnosis of disease, our results are illustrative of the t-CyCIF approach and specific findings might not prove statistically significant when tested on larger, well-controlled sets of human samples.

There is little or no evidence that antigenicity falls across the board in t-CyCIF as cycle number increases; signal-to-noise ratios can even increase due to falling background auto-fluorescence. When samples are stained with the same antibodies in different t-CyCIF cycles, repeatability is high (as measured by correlation in staining intensity on a cell-by-cell basis) as is reproducibility across two successive slices of tissue (as measured by overlap in intensity distributions). Moreover, for the majority of antibodies tested, order of use is not critical. For some antibodies fluorescence intensity increases with cycle number and for others it decreases; these factors need to be considered when developing a staining strategy. While the precise reasons for variation in staining with cycle number are not known such variation is reproducible across specimens, suggesting that it reflects properties of the epitope or antibody and not the t-CyCIF process *per se* , variation in staining can be minimized by staining all specimens with the same antibodies in the same order (which also represents the most practical approach). However, this solution is likely to be insufficient for creation of large-scale t-CyCIF datasets in which diverse tissues will be compared with each other (e.g. in proposed tissue atlases \[[@bib10]\]) and it will therefore be important to identify antibodies for which cycle number has minimal impact and to create effective methods to correct for those fluctuations that do occur (e.g. inclusion of staining controls).

As an initial application of t-CyCIF, we examined a cancer resection specimen that includes PDAC, healthy pancreas and small intestine. Images were segmented and fluorescence intensities in \~10^5^ whole cells calculated for 24 antibody channels plus a DNA stain. Integrating intensities in this manner does not make use of the many subcellular features visible in t-CyCIF images and therefore represents only a first step in data analysis. We find that expression of vimentin and E-cadherin, classical markers of epithelial and mesenchymal cells, are strongly anti-correlated at a single-cell level and that malignant tissue is skewed toward EMT, consistent with prior knowledge on the biology of pancreatic cancer ([@bib58]). The WNT and ERK/MAPK pathways are known to play important roles in the development of PDAC ([@bib24]), but the relationship between the two pathways remains controversial. t-CyCIF reveals a negative correlation between β-catenin levels (a measured of WNT pathway activity) and pERK (a measure of MAPK activity) in cells found in some regions of PDAC, non-malignant small intestine and pancreas, a positive correlation in other regions and no significant correlation in yet others. Thus, the full range of discordant observations found in the literature can be recapitulated within a single tumor, emphasizing the wide diversity of signaling states observable at a single-cell level.

As a second application of t-CyCIF, we studied within-tumor heterogeneity in GBM, a brain cancer with multiple histological subtypes whose differing properties impact prognosis and therapy ([@bib35]; [@bib38]). Clustering reveals multiple phenotypic classes intermingled at multiple spatial scales with no evidence of recurrent patterns. In the GBM we have studied in detail, heterogeneity on a scale of 10--100 cell diameters is as great as it is between distinct lobes. The proportion of cells from different clusters also varies dramatically from one tumor lobe to the next. Although it is not yet possible to link t-CyCIF clusters and known histological subtypes, cell-to-cell heterogeneity on these spatial scales are likely to impact the interpretation of small biopsies (e.g. a core needle biopsy) of a large tumor sample; the data also emphasize the inherent limitation in examining only a small part of a large tumor specimen (e.g. to save time on image acquisition). At the same time, it is important to note that cell-to-cell heterogeneity is caused by processes operating on a variety of time scales, only some of which are likely to be relevant to therapeutic response and disease progression. For example, some cell-to-cell differences visible in GBM images arise from a cyclic process, such as cell cycle progression, whereas others appear to involve differences in cell lineage or clonality. Methods to correct for the effects of variation in cell cycle state have been worked out for single-cell RNA-sequencing ([@bib22]), but will require further work in imaging space.

In a third application of t-CyCIF, we characterized tumor-immune cell interactions in a renal cell tumor. Immune checkpoint inhibitors elicit durable responses in a portion of patients with diverse types of cancer, but identifying potential responders and non-responders remains a challenge. In those cancers in which it has been studied ([@bib31]), quantification of single checkpoint receptors or ligands by IHC lacks sufficient positive and negative predictive value to stratify therapy or justify withholding checkpoint inhibitors in favor of small molecule therapy ([@bib43]). Multivariate predictors based on multiple markers such as CD3, CD4, CD8, PD-1 etc. appear to be more effective, but still underperform in patient stratification ([@bib49]) probably because cells other than CD8 +lymphocytes affect therapeutic responsiveness. In this paper, we perform a simple analysis to show that tumor infiltrating lymphocytes can be subtyped by t-CyCIF and analyzed for the proximity of PD-1 and PD-L1 at a single-cell level. Next steps involve thorough interrogation of immuno-phenotypes by multiplex imaging to relate staining patterns in images to immune cell classes previously defined by flow cytometry and to identify immune cell states that fall below the limit of detection for existing analytical methods.

In conclusion, t-CyCIF is a robust, easy to implement approach to multi-parametric tissue imaging applicable to many types of tumors and tissues; it allows investigators to mix and match antibodies depending on the requirements of a specific type of sample. To create a widely available community resource, we have posted antibody lists, protocols and example data at [http//www.cycif.org](http://www.cycif.org) and are currently updating this information on a regular basis. Highly multiplexed histology is still in an early stage of development and better methods for segmenting cells, quantifying fluorescence intensities and analyzing the resulting data are in development by multiple groups. The resulting ability to quantify cell-to-cell heterogeneity may enable reconstruction of signaling network topologies in situ ([@bib16]; [@bib42]) by exploiting the fact that protein abundance and states of activity fluctuate from one cell to the next; when fluctuations are well correlated, they are likely to reflect causal associations ([@bib53]). We expect t-CyCIF to be complementary to, and used in parallel with other protein and RNA imaging methods such as FISSEQ ([@bib25]) or DEI ([@bib56]) that may have higher sensitivity or greater channel capacity. A particularly important task will be cross-referencing tumor cell types identified by single-cell genomics or multi-color flow cytometry with those identified by multiplexed imaging, making it possible to precisely define the genetic geography of human cancer and infiltrating immune cells.
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Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\             Designation                                             Source or reference       Identifiers                                                      Additional information
  (species) or resource                                                                                                                                                        
  ------------------------- ------------------------------------------------------- ------------------------- ---------------------------------------------------------------- -------------------------------------------------------------
  Biological sample\        TMA:TMA-1207                                            Protein Biotechnologies   Cat: TMA-1207                                                    <http://www.proteinbiotechnologies.com/pdf/TMA-1207.pdf>
  (human tissue specimen)                                                                                                                                                      

  Biological sample\        TMA:MTU481                                              Biomax                    Cat: MTU-481                                                     <https://www.biomax.us/tissue-arrays/Multiple_Organ/MTU481>
  (human tissue specimen)                                                                                                                                                      

  Antibody                  Alexa-488 anti-Rabbit\                                  ThermoFisher Scientific   Cat: A-11034\                                                    Dilution 1:2000
                            antibodies (Fab)                                                                  (RRID:[AB_2576217](https://scicrunch.org/resolver/AB_2576217))   

  Antibody                  Alexa-555 anti-Rat\                                     ThermoFisher Scientific   Cat: A-21434\                                                    Dilution 1:2000
                            antibodies                                                                        (RRID:[AB_141733](https://scicrunch.org/resolver/AB_141733))     

  Antibody                  Alexa-647 anti-Mouse\                                   ThermoFisher Scientific   Cat: A-21236\                                                    Dilution 1:2000
                            antibodies (Fab)                                                                  (RRID:[AB_141725](https://scicrunch.org/resolver/AB_141725))     

  Chemical compound,\       Hoechst 33342                                           ThermoFisher Scientific   Cat: H3570                                                       <https://www.thermofisher.com/order/catalog/product/H3570>
  drug                                                                                                                                                                         

  Software, algorithm       ImageJ                                                  PMID:22930834             RRID: [SCR_003070](https://scicrunch.org/resolver/SCR_003070)    <https://imagej.nih.gov/ij/>

  Software, algorithm       Matlab                                                  MathWorks, Inc.           RRID:[SCR_001622](https://scicrunch.org/resolver/SCR_001622)     

  Software, algorithm       Ashlar                                                  Laboratory of Systems\    RRID:[SCR_016266](https://scicrunch.org/resolver/SCR_016266)     <https://github.com/sorgerlab/ashlar> (copy archived at\
                                                                                    Pharmacology, Harvard\                                                                     <https://github.com/elifesciences-publications/ashlar>)
                                                                                    Medical School                                                                             

  Software, algorithm       BaSiC                                                   Helmholtz Zentrum\        RRID: [SCR_016371](https://scicrunch.org/resolver/SCR_016371)    <https://www.nature.com/articles/ncomms14836>
                                                                                    München                                                                                    

  Other                     [www.cycif.org](http://www.cycif.org)                   Laboratory of Systems\    RRID:[SCR_016267](https://scicrunch.org/resolver/SCR_016267)     Online resource for\
                                                                                    Pharmacology, Harvard\                                                                     cyclic immunofluorescence
                                                                                    Medical School                                                                             

  Other                     [lincs.hms.harvard.edu](http://lincs.hms.harvard.edu)   HMS LINCS Center          RRID:[SCR_016370](https://scicrunch.org/resolver/SCR_016370)     Additional data/image\
                                                                                                                                                                               resource for t-CyCIF
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Key resources, reagents and software used in this study are listed in Key resources table and also online at the HMS LINCS Center Publication Page <http://lincs.hms.harvard.edu/lin-elife-2018/> (RRID:[SCR_016370](https://scicrunch.org/resolver/SCR_016370)). This page provides links to an OMERO image database from which individual images can be obtained; stitched and registered image panels can be obtained at [www.cycif.org](http://www.cycif.org) (RRID:[SCR_016267](https://scicrunch.org/resolver/SCR_016267)) and a video illustrating the t-CyCIF method can be found at <https://vimeo.com/269885646>. The data on staining repeatability shown in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} are complex and are available in a Jupyter notebook at <https://github.com/sorgerlab/lin_elife_2018_tCyCIF_plots> ([@bib34]; copy archived at <https://github.com/elifesciences-publications/lin_elife_2018_tCyCIF_plots>).

Patients and specimens {#s4-1}
----------------------

Formalin fixed and paraffin embedded (FFPE) tissues from were retrieved from the archives of the Brigham and Women's Hospital as part of discarded/excess tissue protocols or obtained from commercial vendors. The Institutional Review Board (IRB) of the Harvard Faculty of Medicine last reviewed the research described in this paper on 2/16/2018 (under IRB17-1688) and judged it to 'involve no more than minimal risk to the subjects' and thus eligible for a waiver of the requirement to obtain consent as set out in 45CFR46.116(d).

Tumor tissue and FFPE specimens were collected from patients under IRB-approved protocols (DFCI 11--104) at Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts. Tonsil samples used in [Figure 1](#fig1){ref-type="fig"} were purchased from American MasterTech (CST0224P). Tissue microarrays for analyses in [Figure 4D and E](#fig4){ref-type="fig"} were obtained from Biomax (Cat. MTU481); detailed information can be found online at <https://www.biomax.us/tissue-arrays/Multiple_Organ/MTU481>. Tissue microarrays (TMA) for diverse healthy tissues and tumor analyses were obtained from Protein Biotechnologies (Cat. TMA-1207).

Reagents and antibodies {#s4-2}
-----------------------

All conjugated and unconjugated primary antibodies used in this study are listed in [Table 2](#table2){ref-type="table"}. Indirect immunofluorescence was performed using secondary antibodies conjugated with Alexa-647 anti-Mouse (Invitrogen, Cat. A-21236), Alexa-555 anti-Rat (Invitrogen, Cat. A-21434) and Alexa-488 anti-Rabbit (Invitrogen, Cat. A-11034). 10 mg/ml Hoechst 33342 stock solution was purchased from Life Technologies (Cat. H3570). 20xPBS was purchased from Santa Cruz Biotechnology (Cat. SC-362299). 30% hydrogen peroxide solution was purchased from Sigma-Aldrich (Cat. 216763). PBS-based Odyssey blocking buffer was purchased from LI-COR (Cat. 927--40150). All reagents for the Leica BOND RX were purchased from Leica Microsystems. HCS CellMask Red Stain and Mito-tracker Green stains were purchased from ThermoFischer (catalog numbers H32712, R37112 and M751, respectively).

Pre-processing and pre-staining tissues for t-CyCIF {#s4-3}
---------------------------------------------------

### Automated dewaxing, rehydration and pre-staining {#s4-3-1}

Pre-processing of FFPE tissue and tumor slices mounted on slides was performed on a Leica BOND RX automated stained using the protocol shown in [Table 3](#table3){ref-type="table"}.

10.7554/eLife.31657.041

###### Breakdown of individual steps performed for dewaxing and antigen retrieval on a Leica BOND.

  Step   Reagent               Supplier   Incubation (min)   Temp. (°C)
  ------ --------------------- ---------- ------------------ ------------
  1      \*No Reagent          N/D        30                 60
  2      BOND Dewax Solution   Leica      0                  60
  3      BOND Dewax Solution   Leica      0                  R.T.
  4      BOND Dewax Solution   Leica      0                  R.T.
  5      200 proof ethanol     User\*     0                  R.T.
  6      200 proof ethanol     User\*     0                  R.T.
  7      200 proof ethanol     User\*     0                  R.T.
  8      Bond Wash Solution    Leica      0                  R.T.
  9      Bond Wash Solution    Leica      0                  R.T.
  10     Bond Wash Solution    Leica      0                  R.T.
  11     Bond ER1 solution     Leica      0                  99
  12     Bond ER1 solution     Leica      0                  99
  13     Bond ER1 solution     Leica      20                 99
  14     Bond ER1 solution     Leica      0                  R.T.
  15     Bond Wash Solution    Leica      0                  R.T.
  16     Bond Wash Solution    Leica      0                  R.T.
  17     Bond Wash Solution    Leica      0                  R.T.
  18     Bond Wash Solution    Leica      0                  R.T.
  19     Bond Wash Solution    Leica      0                  R.T.
  20     IF Block              User\*     30                 R.T.
  21     Antibody Mix          User\*     60                 R.T.
  22     Bond Wash Solution    Leica      0                  R.T.
  23     Bond Wash Solution    Leica      0                  R.T.
  24     Bond Wash Solution    Leica      0                  R.T.
  25     Hoechst Solution      User\*     30                 R.T.
  26     Bond Wash Solution    Leica      0                  R.T.
  27     Bond Wash Solution    Leica      0                  R.T.
  28     Bond Wash Solution    Leica      0                  R.T.

Steps 2--10: Dewaxing and Rehydration with Leica Bond Dewax Solution Cat. AR9222.

Steps 11--14: Antigen retrieval with BOND Epitope Retrieval solution 1 (ER1; Cat. AR9961).

Steps 15--19: Washing with Leica Bond Wash Solution (Cat. AR9590).

Steps 20--28 Pre-staining procedures as shown in [Figure 1A](#fig1){ref-type="fig"}:

Step 20: IF Block - Immunofluorescence blocking in Odyssey blocking buffer (LI-COR, Cat. 927401).

Step 21: Antibody Mix - Incubation with secondary antibodies diluted in Odyssey blocking buffer.

Step 25: Staining with Hoechst 33342 at 2 μg/ml (w/v) in in Odyssey blocking buffer.

### Manual dewaxing, rehydration and pre-staining {#s4-3-2}

In our experience dewaxing, rehydration and pre-staining can also be performed manually with similar results. For manual pre-processing, FFPE slides were first incubated in a 60°C oven for 30 min. To completely remove paraffin, slides were placed in a glass slide rack and then immediately immersed in Xylene in a glass staining dish (Wheaton 900200) for 5 min and subsequently transferred to another dish containing fresh Xylene for 5 min. Rehydration was achieved by sequentially immersing slides, for 3 min each, in staining dishes containing 100% ethanol, 90% ethanol, 70% ethanol, 50% ethanol, 30% ethanol, and then in two successive 1xPBS solutions. Following rehydration, slides were placed in a 1000 ml beaker filled with 500 ml citric acid, pH 6.0, for antigen retrieval. The beaker containing slides and citric acid buffer was microwaved at low power until the solution was at a boiling point and maintained at that temperature for 10 min. After cooling to room temperature, slides were washed 3 times with 1xPBS in vertical staining jars.

### Prestaining {#s4-3-3}

Dewaxed specimens were blocked by incubation with Odyssey blocking buffer for 30 mins by applying the buffer to slides as a 250--500 μl droplet at room temperature; evaporation was minimized by using a slide moisture chamber (Scientific Device Laboratory, 197-BL). Slides were then pre-stained by incubation with diluted secondary antibodies (listed above) for 60 min, followed by washing three times with 1xPBS. Finally, slides were incubated with Hoechst 33342 (2 μg/ml) in 250--500 μl Odyssey blocking buffer for 30 min in a moisture chamber and washed three times with 1xPBS in vertical staining jars. After imaging, cells were subjected to a round of fluorophore inactivation (see below). Following fluorophore inactivation, slides were washed four times with 1x PBS by dipping them in a series of vertical staining jars to remove residual inactivation solution.

Performing cyclic immunofluorescence {#s4-4}
------------------------------------

All primary antibodies (fluorophore-conjugated and unconjugated) were diluted in Odyssey blocking buffer. Slides carrying tissues that had been subjected to pre-staining, or to a previous t-CyCIF stain and bleach cycle, were incubated at 4°C for \~12 hr with diluted primary or fluorophore-conjugated antibody (250--500 μl per slide) in a moisture chamber. Long incubation times were a matter of convenience and many antibodies only require short incubation with sample. Slides were then washed four times in 1x PBS by dipping in a series of vertical staining jars.

For indirect immunofluorescence, slides were incubated in diluted secondary antibodies in a moisture chamber for 1 hr at room temperature followed by four washes with 1xPBS. Slides were incubated in Hoechst 33342 at 2 μg/ml in Odyssey blocking buffer for 15 min at room temperature, followed by four washes in 1xPBS. Stained slides were mounted prior to image acquisition (see the Mounting section below).

### Primary antibodies {#s4-4-1}

For t-CyCIF, we selected commercial antibodies previously validated by their manufacturers for use in immunofluorescence, immunocytochemistry or immunohistochemistry (IF, ICC or IHC). When possible, we checked antibodies on reference tissue known to express the target antigen, such as immune cells in tonsil tissue or tumor-specific markers in tissue microarrays. The staining patterns for antibodies with favorable signal-to-noise ratios were compared to those previously reported for that antigen by conventional antibodies. An updated list of all antibodies tested to date can be found at <http://www.cycif.org>. In current practice, the degree of validation is quantified on a level between 0 and 2: 'Level 0' represents antibodies with inconsistent or no staining in tissues for which the antigen is thought to be present based on published data; 'Level 1' represents the expected pattern of positive staining in a limited number of tissues types (e.g. CD4 antibody in tonsil tissue alone); 'Level 2' represents the expected pattern of positive staining in all tissues or tumor types tested (N \>= 3). Higher levels will be assigned in the future to antibodies that have undergone extensive validation; for example, side-by-side comparison of against an established IHC positive control. Overall, the validation of primary antibodies used in this study is not meaningfully greater what has already been done by commercial vendors using conventional IF or IHC.

### Mounting and de-coverslipping {#s4-4-2}

Immediately prior to imaging, slides were mounted with 1xPBS or, if imaging was expected to take longer than 30 min, for example, in the case of samples larger than 2--4 cm^2^ (corresponding to about 200 fields of view with a 10X objective) PBS was supplement with 10% Glycerol. Slides were covered using 24 × 60 mm No. one coverslips (VWR 48393--106) to prevent evaporation while facilitating subsequent de-coverslipping via gravity. Following image acquisition, slides were placed in a vertical staining jar containing 1xPBS for at least 15 min. Coverslips were released from slides (and the tissue sample) via gravity as the slides were slowly drawn out of the staining jar.

### Fluorophore inactivation (bleaching) {#s4-4-3}

After imaging, fluorophores were inactivated by placing slides horizontally in 4.5% H~2~O~2~ and 24 mM NaOH made up in PBS for 1 hr at RT in the presence of white light. Following fluorophore inactivation, slides were washed four times with 1x PBS by dipping them in a series of vertical staining jars to remove residual inactivation solution.

Image acquisition {#s4-5}
-----------------

Stained slides from each round of CyCIF were imaged with a CyteFinder slide scanning fluorescence microscope (RareCyte Inc. Seattle WA) using either a 10X (NA = 0.3) or 40X long-working distance objective (NA = 0.6). Imager5 software (RareCyte Inc.) was used to sequentially scan the region of interest in four fluorescence channels. These channels are referred to by the manufacturer as a: (i) 'DAPI channel' with an excitation filter having a peak of 390 nm and half-width of 18 nm and an emission filter with a peak of 435 nm and half-width of 48 nm; (ii) 'FITC channel' having a 475/28 nm excitation filter and 525/48 nm emission filter (iii); 'Cy3 channel' having a 542/27 nm excitation filter and 597/45 nm emission filter and (iv); 'Cy5 channel' having a 632/22 nm excitation filter and 679/34 nm emission filter. Imaging was performed with 2 × 2 binning to increase sensitivity, shorten exposure time and reduce photo bleaching. We have tested slide scanners from several other manufacturers (e.g. a Leica Aperio Digital Pathology Slide Scanner, GE IN-Cell Analyzer 6000 and GE Cytell Cell Imaging System) and found that they too can be used to acquire images from samples processed by t-CyCIF. Slides can also be analyzed on conventional microscopes, but the field of view is typically smaller, and an automated stage is required for accurate stitching of individual fields of view into a complete image of a tissue.

Super-resolution microscopy {#s4-6}
---------------------------

We acquired 3D-SIM images on a Deltavision OMX V4 Blaze (GE Healthcare) with a 60x/1.42N.A. Plan Apo oil immersion objective lens (Olympus) and three Edge 5.5 sCMOS cameras (PCO). Two to three micron z-stacks were collected with a z-step of 125 nm or 250 nm and with 15 raw images per plane. To minimize spherical aberration, immersion oil matching was used for each sample as described by [@bib21]). except that we measured point spread functions of point-like structures within the sample as opposed to beads on a separate slide. DAPI fluorescence was excited with a 405 nm laser and collected with a 477/35 emission filter, Alexafluor 488 with a 488 nm laser and a 528/48 emission filter, Alexa fluor 555 with a 568 nm laser and a 609/37 emission filter, and Alexa fluor 647with a 642 nm laser and a 683/40 emission filter. All stage positions were saved in softWorX to be revisited later. Super-resolution images were computationally reconstructed from the raw data sets with a channel-specific, measured optical transfer function and a Wiener filter constant of 0.001 using CUDA-accelerated 3D-SIM reconstruction code based on [@bib18]). A comparison of properties of different imaging platforms used in this study are shown in [Table 1](#table1){ref-type="table"}.

Image processing {#s4-7}
----------------

Quantitative analysis of tissue images is challenging, in large part because cells are close together and embedded in a complex extracellular environment. Background can be uneven across large images and signal-to-noise ratios relatively low, particularly in the case of tissues with high auto-fluorescence and low signal antibodies (e.g. phospho-protein antibodies). We have only started to tackle these issues in the case of high-dimensional t-CyCIF data and users are encouraged to check for updates on [www.cycif.org](http://elife2.kriyadocs.com/www.cycif.org) and implement their own approaches.

### Background subtraction and image registration {#s4-7-1}

Background subtraction was performed using the previously established rolling ball algorithm (with a 50-pixel radius) in ImageJ. Adjacent background-subtracted images from the same sample were then registered to each using an ImageJ script as described previously ([@bib28]). All images with 2×2 binning in acquisition were partially de-convoluted with unsharp masking. DAPI images from each cycle were used to generate reference coordinates by Rigid-body transformation. To generate virtual hyper-stacked images, the transformed coordinates were applied to images from four channel imaging of each t-CyCIF cycle.

### Single-cell segmentation and quantification {#s4-7-2}

To obtain intensity values for single cells, images were segmented using a previously described ([@bib28]) Watershed algorithm based on nuclear staining by Hoechst 33342. Images were initially thresholded using the OTSU algorithm and binarized in the Hoechst channel, which was then used to generate a nuclear mask image. The mask images were then subjected to the Watershed algorithm in ImageJ to obtain single-cell regions of interest (ROIs). From the nuclei, the cytoplasm was captured by centripetal expansion of either of 3 pixels in images obtained with a 10X objective or of 6 pixels in images obtained with a 40X objective, until cell reaching the cell boundaries (cell membrane). The cytoplasm was then defined as the region between the cell membrane and the nucleus. Following cell segmentation, these cell boundaries were used to compute mean and integrated intensity values from all channels. Because ROIs are (initially) defined only by the nuclear signal, this approach is likely to over- or under- segment cells with irregular shapes, which can lead to nuclear, cytosolic or cell membrane 'signal contamination' between neighboring and/or stacked cells. Further experimental (e.g. including membrane markers to guide whole-cell rather than nuclear-only segmentation) and analytical algorithms to more accurately segment individual cells (e.g. using deep learning methods to register and apply additional features) would help to improve segmentation. All imageJ scripts used in this manuscript can be found in our Github repository (<https://github.com/sorgerlab/cycif> \[[@bib27]\]; copy archived at [https://github.com/elifesciences-publications/cycif](https://github.com/elifesciences-publications)).

### Image stitching, shading and flat-field correlation {#s4-7-3}

The BaSiC algorithm ([@bib37]) was used for shade and flat-field correction in the create of the multi-panel montage images shown in [Figures 2B](#fig2){ref-type="fig"}, [6B](#fig6){ref-type="fig"}, [9A](#fig9){ref-type="fig"} and [11A](#fig11){ref-type="fig"}. Additional information can be found on the BaSiC website (<https://www.helmholtz-muenchen.de/icb/research/groups/quantitative-single-cell-dynamics/software/basic/index.html>). An example of the performance of BaSiC is shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}. The ImageJ plugin of BaSiC was applied for whole image stacks using the default options. After processing with BaSiC, images stack were stitched with ImageJ/Fiji 'Grid stitch' plugin with default options. ASHLAR was used to stich, register and scale images available at <http://www.cycif.org/>.

### Time considerations {#s4-7-4}

We believe that the greater time invested in t-CyCIF as compared to conventional IF IHC must be placed in the context of the much greater amount of data generate from a t-CyCIF experiment. It is also important to note that while t-CyCIF can be relatively slow when a single sample is processed it can easily be performed in parallel on multiple samples. As a practical example, we usually stain 30 slides in parallel (each involving 100-200 fields of view); in the case of TMAs, \>80 samples can be assembled on each slide, so up to 2400 samples can be processed in parallel. With a single scanner, 30 slides can be scanned (average scan time \~10 min) in about 6 hr. Photo-inactivation and washing steps take \~1 to 1.5 hr, after which an additional round of staining is initiated. As a matter of convenience, we usually perform staining overnight. Hence, one user can generate data for 90 channels and 1800 images per day. Thus, \~10 work days are required to generate 900 channels/18,000 images. Further time needs to be allotted for registration and stitching (\~12--18 hr of computing time) and quantification (\~24--48 hr computing time, depending on cell density). Overall, we believe that this is a reasonable level of throughput; moreover we have not yet attempted to optimize it using fluidic devices, automated stainers etc. We also note that the throughput of t-CyCIF compares favorably with other tissue-imaging platforms and single-cell transcriptome profiling.

Analysis of tissue integrity over cycles {#s4-8}
----------------------------------------

We purchased a TMA (MTU481, Biomax Inc, <https://www.biomax.us/tissue-arrays/Multiple_Organ/MTU481>) to test the impact of cycle number on tissue integrity. Images were captured and processed as described above. The registered image stacks were then segmented and nuclei counts for each core and each cycle were recorded. All values were normalized to the number of nuclei from the first cycle of a particular core biopsy and the fractional normalized nuclei count shown at each staining cycle.

Calculation of intensity overlap between different cycles and dynamic range {#s4-9}
---------------------------------------------------------------------------

To compare staining patterns between different cycles within the same specimen, we calculated overlap integrals. First, we determined the distribution of intensity data averaged over each single cell and for each t-CyCIF cycles. The area under the curve of these distributions was calculated by trapezoidal numerical integration using 'trapz' function in Matlab ([@bib18]). The ratio of the area under the curve (AUC) for different cycles, samples or antibodies was calculated and the overlap scores then computed as:$$Overlap\, score = overlap\, AUC/total\, AUC$$

The dynamic range (DR) of fluorescence intensities for a given antibody was calculated as a rough estimate of the signal-to-noise ratio; SNR. The calculation was performed as follows: first, pixel-by-pixel intensity data was extracted from a t-CyCIF image; the DR was then calculated as the ratio of the intensities of the 95th and 5th percentile values and represented on a log scale. High DR values indicate a favorable SNR. Intensities below the 5th percentile were considered to be background noise.

High-dimensional single-cell analysis by t-SNE {#s4-10}
----------------------------------------------

Raw intensity data generated from registered and segmented images were imported into Matlab and converted to comma separated value (csv) files. The viSNE implementation of t-SNE and EMGM algorithms from the CYT single-cell analysis package were obtained from the Pe'er laboratory at Columbia University ([@bib1]). Intensity-based measurements (such as flow cytometry or imaging cytometry) of protein expression have approximately log-normal distribution ([@bib3]), hence, t-CyCIF raw intensity values were first transformed in log or in inverse hyperbolic sine (*asinh*) using the default Matlab function or the *CYT* package ([@bib1]), respectively. Between-sample variation was normalized on a per-channel basis by using the *CYT* package to align intensity measurements that encompass values between 1st and the 99th percentile. Data files were aggregated and used to generate viSNE plots. All viSNE/t-SNE analyses used the following settings: perplexity −30, epsilon = 500, lie factor = 4 for initial 100 iterations and lie factor −1 for remaining iterations.

Regional and neighboring analysis using K-nearest neighbors (KNN) methods {#s4-11}
-------------------------------------------------------------------------

To determine whether PD-1 and PD-L1 expressing cells are sufficiently close for the receptor and ligand to interact, the spatial densities for PD1^+^ and PDL1^+^ cells were estimated using a k nearest neighbors (kNN) model with k = 4, corresponding to a \~10 µm smoothing window. Since the density in space of the PD1^+^ or PDL1^+^ cells at any point in that space is proportional to the probability of that cell having a centroid there, the co-occurrence probability at a point was therefore proportional to the product of the spatial densities for both cell types at a point. To normalize for the difference in total PDL1+ or PD1+ cells between regions of the tissue corresponding to tumor and stroma, we calculated spatial probabilities for the different regions in the specimen separately. [Figure 9---figure supplement 1](#fig9s1){ref-type="fig"} shows the distribution of co-occurrence densities for stroma and tumor relevant to a clear-cell carcinoma shown in [Figure 9](#fig9){ref-type="fig"}.

Calculating Shannon entropy values {#s4-12}
----------------------------------

Images were divided into regular grids and 1000 cells from each region used to calculate the non-parametric Shannon entropy as follows:$$Shanon\, Entropy\ \left( s \right) = \  - \sum\limits_{i}s_{i}^{2}log\left( s_{i}^{2} \right)$$where s~i~ is the per-pixel intensity of signal **s** at a given point. Normalized Shannon entropy as calculated as E~normalized~ = E~region~/E~sample.~

Expectation--Maximization Gaussian mixtures (EMGM) clustering {#s4-13}
-------------------------------------------------------------

To determine an appropriate number of clusters (*k*) for analysis of the GBM tumor shown in [Figures 11](#fig11){ref-type="fig"} and [12](#fig12){ref-type="fig"} and in [Figure 12---figure supplement 2](#fig12s2){ref-type="fig"} we determined negative log-likelihood-ratios for various values of *k*. For each choice of cluster number *n*, the likelihood-ratio was calculated for a Gaussian mixture model with *n = k-1* and with *n = k* and the ratio then plotted relative to k. The EMGM algorithm was initialized 30 times for each value of *k* and it converged in all instances. The inflection at k = 8 (red arrow) suggests that inclusion of additional clusters (k \> 8) explains a smaller, distinct source of variation in the data ([Figure 12---figure supplement 1](#fig12s1){ref-type="fig"}). As an alternative, k = 12 was also explored in [Figure 12---figure supplement 2](#fig12s2){ref-type="fig"}. Intensity values from all antibody channels (plus area and Hoechst intensity) were used for clustering.

Data availability {#s4-14}
-----------------

 All data generated or analyzed during this study are included in the manuscript and supporting files. Intensity data used to generate figures is available in supplementary materials and can be downloaded from the HMS LINCS Center Publication Page (<http://lincs.hms.harvard.edu/lin-elife-2018/>) (RRID:[SCR_016370](https://scicrunch.org/resolver/SCR_016370)).

Code availability {#s4-15}
-----------------

Code and scripts used in this study are listed in Key resources table and also on-line at the HMS LINCS Center publication page (<http://lincs.hms.harvard.edu/lin-elife-2018/>). ImageJ is available at <https://imagej.nih.gov/ij/>

BaSic is available at <https://www.helmholtz-muenchen.de/icb/research/groups/quantitative-single-cell-dynamics/software/basic/index.html>. Matlab scripts used in this paper and the ASHLAR registration/stitching algorithm is available at our GitHub repositories (<https://github.com/sorgerlab/cycif> and <https://github.com/sorgerlab/ashlar> ([@bib34]; [@bib27]). A Jupyter notebook for futher exploration of data in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} is available at <https://github.com/sorgerlab/lin_elife_2018_tCyCIF_plots> ([@bib33]; copy archived at <https://github.com/elifesciences-publications/lin_elife_2018_tCyCIF_plots>).

Image availability {#s4-16}
------------------

All images can be obtained from an OMERO image database via links found at the HMS LINCS Center Publication Page <http://lincs.hms.harvard.edu/lin-elife-2018/> (RRID: [SCR_016370](https://scicrunch.org/resolver/SCR_016370)). Stitched and registered image composites can be obtained at [www.cycif.org](http://www.cycif.org). (RRID:[SCR_016267](https://scicrunch.org/resolver/SCR_016267)) and via links found there.
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All data generated or analyzed during this study are included in the manuscript and supporting files. Intensity data used to generate figures is available in supplementary materials and can be downloaded from the HMS LINCS Center Publication Page (<http://lincs.hms.harvard.edu/lin-elife-2018/>) (RRID:SCR_016370). The images described are available at <http://www.cycif.org/> (RRID:SCR_016267) and via and OMERO server as described at the LINCS Publication Page.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A simple open-source method for highly multiplexed imaging of single cells in tissues and tumours\" for consideration by *eLife*. Your article has been reviewed by Arup Chakraborty as the Senior Editor, a Reviewing Editor, and three reviewers. The following individuals involved in review of your submission have agreed to reveal their identity: Carsten Marr (Reviewer \#2); Péter Horváth (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Overall, the reviewers appreciated the ability to multiplex immunofluorescence in FFPE samples using cyclic chemistry to measure expression and localization of several proteins in single cells. The open-source tools for the image processing pipeline were also thought to be of much interest to the community.

Essential revisions:

As discussed in our earlier correspondence, one concern that arose during deliberations was the lack of a clear discussion of the advance described in this manuscript relative to other contributions in the field, in particular that of Gerdes et al. We appreciate the arguments about lack of adoption of the method described by Gerdes et al., and its proprietary nature, and ultimately believe that for methodological improvements like this, the research community may be the best judge of the relative merits. Nevertheless, we do think it\'s very important to clearly delineate the contributions of the previous work in the field and precisely what the advance is in this present manuscript relative to those contributions, both in the Introduction and Discussion section.

Technically, the reviewers felt that the work lacked sufficient testing to show that order of antigen staining is not affected by cycle number, noting \"This is a well known issue for multiplexed tissue staining and should be analyzed beyond just 4 cycles with 3 antigens. Tissue integrity is compromised after 5 cycles and only quantified to 10 cycles (Figure 1H); the authors claim their methods work to 20 cycles but descriptions of tissue integrity are lacking.\" The recommendation was: \"Retention of antigenicity is only showed up to cycle 4 and for only 3 antigens, although data from higher cycles are used in other figures (20 cycles in Figure S3). Gerdes et al. demonstrates that 8/59 antibodies tested did not maintain full antigenicity after the tissue had been exposed 10 times to dye inactivation solution. We recognize that an experiment to test all possible orders/combinations of antibodies would be time and labor intensive, but we believe antibody validation must include how long antigenicity is preserved through cycles. We suggest the following tests of the methods:

\* Two adjacent tissue slices are stained for 20 cycles with antibodies 1-\>20 and 20-\>1, respectively. The results are shown to be at least qualitatively similar.

\* Maintenance of antigenicity for most, if not all, single antibodies up to 10-20 cycles.\"

Another reviewer noted \"As a quantitative method, I would appreciate an evaluation of the robustness of the single cell measurements over cycles. It would be interesting to see how single cell intensities correlate when stained for the same antigens in cycle 1, cycle 2, cycle 3 etc., maybe even using different fluorophores, or a staining in cycle 1 and again in cycle 10, with other antigen stainings in between. This would add a quantitative level to Figure 2B.\"

Also: \"Would be great to know the authors\' experiences regarding the degradation after 8-20 t-CyCIF cycles, which is only partially discussed. For basic biology discovery studies, it would be great to have a stopping criteria where the number of washing steps saturate and noise takes over the signal, and in potential clinical practice a cycle number until quality is guaranteed would also be desired.\"

We feel that these technical points are important to fully address in a revision.

10.7554/eLife.31657.051

Author response

> Summary:
>
> Overall, the reviewers appreciated the ability to multiplex immunofluorescence in FFPE samples using cyclic chemistry to measure expression and localization of several proteins in single cells. The open-source tools for the image processing pipeline were also thought to be of much interest to the community.
>
> Essential revisions:
>
> As discussed in our earlier correspondence, one concern that arose during deliberations was the lack of a clear discussion of the advance described in this manuscript relative to other contributions in the field, in particular that of Gerdes et al. We appreciate the arguments about lack of adoption of the method described by Gerdes et al., and its proprietary nature, and ultimately believe that for methodological improvements like this, the research community may be the best judge of the relative merits. Nevertheless, we do think it\'s very important to clearly delineate the contributions of the previous work in the field and precisely what the advance is in this present manuscript relative to those contributions, both in the Introduction and Discussion section.

We certainly agree with the reviewer that prior studies should be adequately cited; we had not intended to slight prior work by Gerdes and others (although we agree that we did not do a good job in the first submission). To address this concern we have re-written the Introduction and Discussion section to specifically mention prior work by Gerdes and to make clear that our paper builds on that earlier work.

> Technically, the reviewers felt that the work lacked sufficient testing to show that order of antigen staining is not affected by cycle number, noting \"This is a well known issue for multiplexed tissue staining and should be analyzed beyond just 4 cycles with 3 antigens. Tissue integrity is compromised after 5 cycles and only quantified to 10 cycles (Figure 1H); the authors claim their methods work to 20 cycles but descriptions of tissue integrity are lacking.\" The recommendation was: \"Retention of antigenicity is only showed up to cycle 4 and for only 3 antigens, although data from higher cycles are used in other figures (20 cycles in Figure S3). Gerdes et al. demonstrates that 8/59 antibodies tested did not maintain full antigenicity after the tissue had been exposed 10 times to dye inactivation solution. We recognize that an experiment to test all possible orders/combinations of antibodies would be time and labor intensive, but we believe antibody validation must include how long antigenicity is preserved through cycles. We suggest the following tests of the methods:
>
> \*Two adjacent tissue slices are stained for 20 cycles with antibodies 1-\>20 and 20-\>1, respectively. The results are shown to be at least qualitatively similar.
>
> \*Maintenance of antigenicity for most, if not all, single antibodies up to 10-20 cycles.\"
>
> Another reviewer noted \"As a quantitative method, I would appreciate an evaluation of the robustness of the single cell measurements over cycles. It would be interesting to see how single cell intensities correlate when stained for the same antigens in cycle 1, cycle 2, cycle 3 etc., maybe even using different fluorophores, or a staining in cycle 1 and again in cycle 10, with other antigen stainings in between. This would add a quantitative level to Figure 2B.\"

These are all very important issues and we have spent the extended revision period performing multiple experiments to address them. Three separate 16-cycle antibody swap experiments, each involving two immediately adjacent tissue slides, were performed to study the issue of antibody order of addition. In these studies antibodies against abundant proteins were applied repeatedly to successive specimens from the same tissue block (slides A and B). Abundant proteins are expected to be relatively unaffected by antibody saturation and were used in four cycles spread across 16 cycles total. The impact of cycle number on antibodies against less abundant antigens (which are potentially easier to saturate) was evaluated by swapping them between early and late cycles on slides A and B. This made it possible to assess several issues raised by the reviewers, including (1) the repeatability of staining on a single sample, (2) the reproducibility of staining across specimens, and (3) the effect of swapping between early and late cycles on morphology and fluorescence intensity. We also examined signal to noise ratio and tissue integrity more carefully than previously.

Results from these studies are presented in two new figures (Figure 5, Figure 6 and Figure 6---figure supplement 1) and in a new section of the Results section. Overall, we find little or no evidence that antigenicity falls across the board as cycle number increases. We have confirmed that signal-to-noise ratios can increase with higher cycle number due to lower auto-fluorescence. For a subset of antibodies, we do observe significant changes in fluorescence intensity with cycle number but these can involve both increases and decreases in intensity. When antibodies are used in the same cycle across two samples, a very high degree of repeatability is possible (Figure 6F).

Tissue integrity and not antigenicity appears to be the primary limitation on high-cycle t-CyCIF. We find that about half of all tissue tested can routinely be imaged out to 15 cycles with \<20% loss of cells but that other tissues are less robust. Considerable variability is observed within a single tissue type (data on breast cancer is shown in Figure 4E). In response to the reviewer's concerns we have toned down our claim about "60 channels and 20 cycles" although we now show such an experiment in its entirety in Figure 4F-G and we continue to perform high-cycle t-CyCIF on a routine basis. We speculate that "pre-analytical variables" such fixation conditions, the age of tissue blocks and similar variables strongly influence tissue integrity; we are studying this now and expect to return to it in a future paper.

One additional issue affecting cycle-to-cycle reproducibility is the lack of sensors, in current slide scanners, to measure and adjust the intensity of excitatory illumination. These instruments do not illuminate the back focal plane with the uniformity expected of high resolution microscopes. Because of stage instability it is also difficult to ensure that repeated sampling occurs at the same position in Z. All of these issues can be addressed with additional hardware development and we are fortunate to have recently obtained an NIH STTR grant to co-fund hardware development with RareCyte, manufacturer of the instruments used in this study. We touch very briefly on these issues in the revised Discussion section.

> Also: \"Would be great to know the authors\' experiences regarding the degradation after 8-20 t-CyCIF cycles, which is only partially discussed. For basic biology discovery studies, it would be great to have a stopping criteria where the number of washing steps saturate and noise takes over the signal, and in potential clinical practice a cycle number until quality is guaranteed would also be desired.\"

We appreciate the reviewer's concern: knowing how many cycles can be performed on different types of tissue will be important. The revision now describes a 10-cycle t-CyCIF experiment on a tissue microarray (TMA) comprising 48 core biopsies derived from 16 different healthy tissue types and several breast cancers (Figure 4). To measure tissue integrity, we quantified the number of nuclei and plotted the normalized nuclei count (relative to the pre-staining nuclei count) after each staining cycle (Figure 4D). All samples could undergo 10 cycles of staining with retention of \>70% or cells but integrity varied between different tissue types and across biopsies from the same tumor type (Figure 4E).

We conclude that tissues can reliably be subjected to 8 to 10-cycle t-CyCIF and some specimens maintain their integrity even after 20 cycles. Unfortunately, we do not yet understand the factors underlying differences in tissue integrity except that they are likely to involve biological factors, preanalytical variables (i.e. fixation, age of tissue blocks, mounting, and cutting) and the t-CyCIF process itself. Fortunately, it is very easy to measure tissue integrity empirically after each cycle based on the fraction of nuclei still present in the sample and users of the method need to do this themselves. Future work will be required to develop useful predictors and systematic improvements in cycle number.

[^1]: These authors contributed equally to this work.
